



HAL
open science

Genetic Causes of Functional Adrenocortical Adenomas

Maria-Christina Zennaro, Sheerazed Boulkroun, Fabio Fernandes-Rosa

► **To cite this version:**

Maria-Christina Zennaro, Sheerazed Boulkroun, Fabio Fernandes-Rosa. Genetic Causes of Functional Adrenocortical Adenomas. *Endocrine reviews*, 2017, 38 (6), pp.516-537. 10.1210/er.2017-00189 . hal-03845543

HAL Id: hal-03845543

<https://hal.science/hal-03845543>

Submitted on 9 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Genetic causes of functional adrenocortical adenomas

Maria-Christina Zennaro^{1,2,3}, Sheerazed Boulkroun^{1,2}, Fabio Fernandes-Rosa^{1,2,3}

Affiliations:

¹INSERM, UMRS_970, Paris Cardiovascular Research Center, Paris, France

²Université Paris Descartes, Sorbonne Paris Cité, Paris, France

³Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Service de Génétique, Paris, France

Address correspondence to:

Maria-Christina Zennaro, MD, PhD

INSERM, U970

Paris Cardiovascular Research Center – PARCC

56, rue Leblanc,

75015 Paris – France

Tel : +33 (0)1 53 98 80 42

Fax : + 33 (0)1 53 98 79 52

e-mail: maria-christina.zennaro@inserm.fr

Abbreviations: PA, primary aldosteronism; CS, Cushing syndrome; sCS, subclinical Cushing syndrome; APA, aldosterone producing adenomas; CPA, cortisol producing adenomas; A/CPA, aldosterone and cortisol producing adenoma; ACA, adrenocortical adenoma; BAH: bilateral adrenal hyperplasia; PBMAH, primary bilateral macronodular adrenal hyperplasia; FH, familial hyperaldosteronism

Sources of Funding

This work was funded through institutional support from INSERM and by the Agence Nationale de la Recherche (ANR Blanc 2011, No.: 11-BSV1 005 03, ANR-13-ISV1-0006-01), the Fondation pour la Recherche Médicale (DEQ20140329556), the Programme Hospitalier de Recherche Clinique (PHRC grant AOM 06179), and by grants from INSERM and Ministère Délégué à la Recherche et des Nouvelles Technologies. The laboratory of Dr Maria-Christina Zennaro is also partner of the H2020 project ENSAT-HT grant n° 633983.

Disclosures

The authors have nothing to disclose.

Abstract

Aldosterone and cortisol, the main mineralocorticoid and glucocorticoid hormones in humans, are produced in the adrenal cortex, which is composed of three concentric zone with specific functional characteristics. Adrenocortical adenomas (ACA) may lead to the autonomous secretion of aldosterone responsible for primary aldosteronism, the most frequent form of secondary arterial hypertension. In the case of cortisol production, ACA lead to overt or subclinical Cushing syndrome. Genetic analysis driven by next generation sequencing technology has enabled the discovery, during the last seven years, of the genetic causes of a large subset of ACA. In particular, somatic mutations in genes regulating intracellular ionic homeostasis and membrane potential have been identified in aldosterone producing adenoma. These mutations all promote increased intracellular calcium concentrations, with activation of calcium signaling, the main trigger for aldosterone production. In cortisol producing adenomas, recurrent somatic mutations in *PRKACA* (coding for the cAMP-dependent protein kinase catalytic subunit alpha) affect cyclic AMP-dependent protein kinase A signaling, leading to activation of cortisol biosynthesis. In addition to these specific pathways, the Wnt/ β -catenin pathway appears to play an important role in adrenal tumorigenesis, as β -catenin mutations have been identified in both aldosterone as well as cortisol producing adenomas. This, together with different intermediate states of aldosterone and cortisol co-secretion, raises the possibility that the two conditions share a certain degree of genetic susceptibility. Alternatively, different hits may be responsible for the diseases, with one hit leading to adrenocortical cell proliferation and nodule formation, with the second one specifying the hormonal secretory pattern.

1 **1. Introduction**

2 Adrenal masses are quite common being found in $\approx 3\%$ of the general population with the
3 prevalence increasing with age (1). Functional adrenocortical adenomas are a group of benign
4 tumors of the adrenal cortex autonomously secreting excess hormones. Aldosterone producing
5 adenomas (APA) are responsible for primary aldosteronism (PA), the most frequent form of
6 secondary hypertension. Cortisol producing adenomas (CPA) are responsible for overt or
7 subclinical Cushing syndrome (CS). In addition, both diseases may also result from different
8 forms of adrenal hyperplasia: bilateral adrenal hyperplasia (BAH) in PA and primary bilateral
9 macronodular adrenal hyperplasia (PBMAH) responsible for overt or subclinical CS. Primary
10 pigmented nodular adrenal hyperplasia is a rare condition responsible for overt CS. Unilateral
11 adrenal hyperplasia leading to autonomous aldosterone or cortisol production has also been
12 described. Importantly, in between the two conditions are histological forms of multinodular
13 adrenals where hormone production may be localized to one large nodule or to multiple
14 nodules; sometimes co-secretion of aldosterone and cortisol is observed in one adrenal, either
15 from one adenoma or from distinct adenomas.

16

17 **2. Aldosterone and cortisol biosynthesis in the adrenal cortex**

18 Aldosterone and cortisol are produced in the adrenal cortex, which is composed in humans of
19 three concentric functionally distinct zones. Steroid hormones are produced from cholesterol
20 through sequential enzymatic steps involving different cytochrome P450 enzymes and
21 hydroxysteroid dehydrogenases and the functional properties of each zone results from the
22 expression of specific steroidogenic enzymes and the ability to respond to unique regulatory
23 stimuli. In particular, the outer zona glomerulosa produces aldosterone through the activity of
24 aldosterone synthase (encoded by *CYP11B2*), which catalyzes the three terminal reactions of
25 aldosterone biosynthesis: hydroxylation at position C11 of the steroid intermediate
26 deoxycorticosterone (DOC) yielding corticosterone, followed by a hydroxylation at position

27 C18 yielding 18-hydroxy-corticosterone and a subsequent oxidation of the hydroxyl group at
28 C18, which results in the formation of aldosterone. Cortisol biosynthesis occurs in the zona
29 fasciculata, where the expression of 17 α hydroxylase mediates conversion of 17-deoxy-21-
30 carbon steroids into 17-hydroxy-21-carbon steroids, precursors of cortisol. As 17 α
31 hydroxylase is not expressed in rats and mice, the main glucocorticoid in these species is
32 corticosterone (2). Cortisol is synthesized from 17OH-progesterone through 21-hydroxylation
33 to form 11-deoxycortisol, followed by hydroxylation at position C11 by 11 β -hydroxylase
34 (encoded by *CYP11B1*). The two highly homologous genes *CYP11B2* and *CYP11B1* are
35 located in tandem on human chromosome 8q21-22. Unequal crossing over of the two genes
36 during meiosis results in a chimeric gene composed of the regulatory regions of *CYP11B1*
37 fused to the coding sequence of *CYP11B2*, which is responsible for familial
38 hyperaldosteronism (FH) type 1 (also known as glucocorticoid remediable aldosteronism) (3).
39 Under these conditions, aldosterone synthase expression and aldosterone biosynthesis are
40 regulated by ACTH in the zona fasciculata of the adrenal cortex, rather than by angiotensin II
41 (AngII), with a circadian rhythmicity of aldosterone production following that of cortisol (4)
42 and production of the hybrid steroids 18-hydroxycortisol and 18-oxocortisol (5,6).
43 The main regulators of aldosterone biosynthesis are the renin-angiotensin system, the
44 concentration of extracellular potassium and ACTH (7). The renin-angiotensin system
45 translates changes in renal perfusion or sodium concentration sensed by the distal tubule into
46 changes in aldosterone production from the adrenal cortex, in order to maintain volume and
47 electrolyte homeostasis. AngII acts via the AT1 receptor expressed in zona glomerulosa cells,
48 activating a G α q-phospholipase C mediated pathway leading to increased inositol 1,4,5-
49 triphosphate (IP3) and 1,2-diacylglycerol concentrations. IP3 increases intracellular calcium
50 concentrations by calcium release from intracellular stores.

51 AngII also inhibits the background potassium channel TASK (TWIK-related acid-sensitive
52 potassium channel) and the Na⁺,K⁺-ATPase, leading to cell membrane depolarisation and
53 activation of voltage-gated Ca²⁺ channels, again increasing intracellular calcium
54 concentrations. Extracellular potassium is the other major regulator of aldosterone production,
55 exerting a large amplitude of control over a wide range of potassium concentrations. This is
56 possible because the main ionic conductance of zona glomerulosa cells is that of K⁺ and the
57 cell membrane potential closely follows the equilibrium potential of K⁺ over a large range of
58 extracellular K⁺ concentrations (8). Elevation of the extracellular K⁺ concentration, a decrease
59 in the intracellular K⁺ concentration, inhibition of Na⁺, K⁺-ATPase or closure of potassium
60 channels all lead to cell membrane depolarization, opening of voltage-dependent Ca²⁺
61 channels and an increase in intracellular calcium concentrations resulting in activation of
62 calcium signaling.

63 Increased calcium signalling affects aldosterone production in several ways. Calcium
64 signalling increases activity of cholesterol ester hydrolase with subsequent release of
65 deesterified cholesterol from cytoplasmic stores, promotes cholesterol delivery to the outer
66 mitochondrial membrane and its transfer to the inner mitochondrial membrane by increasing
67 expression of the steroid acute regulatory protein (StAR), and increases the synthesis of
68 cofactors required for p450 cytochrome enzymes (9). Stimulation of *CYP11B2* transcription is
69 mediated by calcium/calmodulin binding and activation of protein kinases regulating
70 phosphorylation of several transcription factors, in particular nuclear receptor subfamily 4
71 group A (NR4A) members 1 and 2 (NURR77 or NGF1B and NURR1), the cyclic AMP-
72 dependent transcription factor ATF-1 and the cyclic AMP-responsive element-binding protein
73 (CREB) (10) (Figure 1A).

74 Cortisol production is regulated by the hypothalamus-pituitary-adrenal (HPA) axis, whereby
75 circadian input and stress stimuli induce release of cortisol via corticotrophin releasing

76 hormone (CRH) -dependent ACTH secretion and cortisol signals back to exert negative
77 feedback on the hypothalamus and the pituitary. In the zona fasciculata (and zona reticularis)
78 of the adrenal cortex, ACTH binds to its receptor MC2R (Melanocortin receptor 2), which
79 signals through a Gas mediated signaling to increase intracellular cAMP levels and to activate
80 protein kinase A (PKA) (Figure 1B) (11). Acute stimulation by ACTH elicits effects on
81 steroidogenesis by regulating cholesterol availability, mobilizing cholesterol from lipid stores
82 and increasing cholesterol transport into mitochondria and by stimulating transcription of
83 steroidogenic genes. Rapid effects occurring within minutes mainly affect StAR activity
84 through phosphorylation, while longer stimulation (days) by ACTH results in transcriptional
85 regulation of StAR as well as steroidogenic enzymes. In particular, PKA signaling activates
86 transcription factors regulating expression of steroidogenic genes, including steroidogenic
87 factor 1 (SF-1), CREB, CRE modulator (CREM), CCAAT/enhancer-binding proteins
88 (C/EBPs), and activator protein 1 (AP-1) (11). ACTH also regulates aldosterone production
89 acutely via cAMP mediated pathways, whereas chronically, ACTH suppresses plasma
90 aldosterone both in human and animal models and downregulates *CYP11B2*, inducing
91 *CYP11B1* expression and promoting a zona fasciculata phenotype (7,12). Long-term exposure
92 to ACTH (weeks or months) stimulates adrenal growth and promotes adrenal cell hypertrophy
93 and hyperplasia. In extreme cases of glucocorticoid deficiency or ACTH excess, as well as in
94 experimental models of CRH or ACTH deficient mice, the trophic effects of the hormone lead
95 to major hyperplasia or atrophy respectively of the inner zones of the adrenal cortex (12). In
96 addition to acting through cAMP, ACTH also stimulates calcium influx in glomerulosa cells
97 by activation of L-type Ca²⁺ channels (9). Many other factors have been shown to modulate
98 aldosterone and cortisol production, including neurotransmitters, cytokines, vascular products,
99 and adipokines, as well as locally produced ACTH acting through a paracrine mechanism
100 (12,13).

101

102 **3. Somatic mutations in APA**

103 PA is due to autonomous aldosterone production from the adrenal cortex and is diagnosed on
104 the basis of hyperaldosteronism associated with suppressed renin and often hypokalemia (14).

105 It is the most common form of secondary hypertension (HT), with a prevalence of 5-10% in
106 patients with arterial hypertension (15,16) and up to 20% in patients with resistant HT (17).

107 PA is associated with increased cardiovascular risk, in particular coronary artery disease,
108 nonfatal myocardial infarction, heart failure, atrial fibrillation, renal damage and stroke (18-
109 20), due to blood-pressure independent effects of aldosterone on cardiac and vascular
110 remodeling (21,22),

111 The majority of cases of PA are due to an APA or to bilateral adrenal hyperplasia (BAH, also
112 called idiopathic hyperaldosteronism). Only in rare cases has unilateral adrenal hyperplasia
113 been described, and aldosterone producing adrenocortical cancers are extremely rare. APA are
114 generally small (< 2 cm in diameter) and are diagnosed by adrenal CT and adrenal venous
115 sampling, which identifies lateralized aldosterone secretion in the presence or absence of a
116 visible adrenal nodule at imaging (14,23). Recent advances in genome technology have
117 allowed identification, during the last five years, of several somatic mutations in APA,
118 providing a pathogenic model for PA development. Whole exome sequencing of paired
119 tumour (somatic) and germline DNA performed by different groups on a total of more than
120 100 APA samples has identified recurrent somatic mutations in genes coding for ion channels
121 (*KCNJ5* (24) and *CACNA1D* (25,26)) and ATPases (*ATP1A1* and *ATP2B3*, (25,27))

122 regulating intracellular ionic homeostasis and cell membrane potential, thus defining APA as
123 a channelopathy. These mutations all promote increased intracellular calcium concentrations,
124 leading to activation of calcium signaling, the main trigger for aldosterone biosynthesis
125 (Figure 1). A small fraction of APA also carries somatic mutations in *CTNNB1*, coding for β -

126 catenin, similar to CPA (see below) and adrenocortical cancer (28,29) (Table 1). In the largest
127 multicenter study published, exploring the prevalence of somatic mutations in *KCNJ5*,
128 *CACNAID*, *ATP1A1* and *ATP2B3* in 474 patients from seven centers belonging to the
129 ENS@T network (European Network for the Study of Adrenal Tumors), somatic mutations
130 were detected in 54% of APA, ranging from 27.2% to 56.8% across different centers (30). In
131 this study, *KCNJ5* mutations were the most prevalent genetic abnormality and were found in
132 38% of APA. Mutations affecting *CACNAID* were the second most prevalent genetic
133 abnormalities being present in 9.3% of cases, while *ATP1A1* and *ATP2B3* mutations were
134 identified in 5.3% and 1.7% of cases respectively. There was no difference in cellular
135 composition (percentage of cells resembling to zona fasciculata (ZF) or zona glomerulosa
136 (ZG)) of APA or in *CYP11B2*, *KCNJ5*, *CACNAID* or *ATP1A1* gene expression in APA across
137 genotypes. Patients with *KCNJ5* mutations were more frequently female, diagnosed younger
138 and with higher plasma potassium concentrations when compared to *CACNAID* mutation
139 carriers or non-carriers. *CACNAID* mutations were associated with smaller adenomas. There
140 was no association between the mutation status and preoperative plasma aldosterone or renin
141 levels, the aldosterone to renin ratio or the number of medications taken before surgery. There
142 was also no association with post-operative blood pressure outcomes, treatment scores at
143 follow-up, cure or improvement of hypertension. These associations were largely center-
144 dependent, which might be due to the heterogeneity of APA that has to be taken into account
145 when considering genotype-phenotype correlations (30).

146 Furthermore, less frequent mutations have been identified in a few genes in patients with
147 peculiar phenotypes of PA, including early-onset PA and tumors cosecreting aldosterone and
148 cortisol (31,32) (Table 1). Recently, somatic mutations in *PRKACA* (coding for the cAMP-
149 dependent protein kinase catalytic subunit alpha) have been reported in patients with APA
150 (32). Using whole exome and targeted sequencing in 122 patients, Rhayem et al identified

151 two somatic heterozygous mutations in *PRKACA*, one of them being the p.Leu206Arg
152 mutation previously reported in CPA (see below). The carrier of this variant had biochemical
153 Cushing syndrome and high expression of 11 β -hydroxylase in the tumor. The second
154 p.His88Asp variant was not associated with cortisol excess, nor with a gain of function of the
155 PKA catalytic activity, leaving open the question of its role in the development of PA.

156

157 **3.1. Pathogenic mechanisms of APA development**

158 *KCNJ5* codes for the G protein-activated inward rectifier potassium channel GIRK4
159 (alternative protein name Kir3.4), which is composed of two membrane-spanning domains
160 (M1 and M2), one pore forming region (H5) and cytoplasmic N- and C-termini that contribute
161 to the pore structure. Recurrent somatic mutations identified in APA cluster within or near the
162 selectivity filter of the channel pore, between amino acids Thr149 to Gly153 (Table 2). They
163 affect its ionic selectivity, rendering the channel permeable to sodium, with increased sodium
164 influx into the cell leading to chronic cell membrane depolarization and opening of voltage-
165 gated calcium channels (24). This in turn, leads to increased intracellular calcium
166 concentrations and activation of calcium signaling (Figure 1A). Transient transfection of
167 *KCNJ5* mutants into adrenocortical cells increase aldosterone production and expression of
168 *CYP11B2* in a calcium-dependent manner (33); in some cases, mutations lead to reduced
169 membrane and total abundance of GIRK4 (34). Surprisingly, transiently transfected *KCNJ5*
170 mutants did not lead to enhanced cell proliferation *ex vivo*, but rather to reduced cell viability
171 or sodium dependent cell death, which does not explain the cell proliferation and APA
172 formation (33,35). Whether these results are due to experimental artefacts, due to high
173 expression of transfected channels leading to excessively increased sodium influx into the
174 cell, which does not reflect the *in vivo* situation, or whether additional hits are required for
175 cell proliferation, remains a matter of debate.

176 *CACNA1D* codes for the $\alpha 1$ subunit of the L-type voltage gated Cav1.3 calcium channel
177 (calcium channel, voltage-dependent, L type, alpha-1d subunit), whereas *ATP1A1* codes for
178 the $\alpha 1$ subunit of the Na^+ , K^+ -ATPase and *ATP2B3* for the plasma membrane calcium-
179 transporting ATPase 3 (PMCA3). Na^+ , K^+ -ATPase and PMCA3 are members of the P-type
180 family of ATPases and are composed of ten transmembrane domains (M1 – M10) with
181 intracellular N- and C-tails. *ATP1A1* mutations affect amino acids in transmembrane helices
182 M1, M4 and M9 of the $\alpha 1$ subunit of the Na^+ , K^+ -ATPase (Table 2). They lead to a loss of
183 pump activity and a reduced affinity for K^+ , as well as to an inward proton or sodium leak,
184 which is proposed to increase aldosterone production through cell membrane depolarization
185 and increased calcium influx, as is observed in the presence of *KCNJ5* mutations (25,27).
186 However, transient transfections of Na^+ , K^+ -ATPase $\alpha 1$ subunits carrying the p.Leu104Arg,
187 p.Val332Gly or p.Gly99Arg mutations in adrenocortical NCI-H295R cells did not modify
188 basal cytosolic calcium levels and hardly increased potassium-stimulated calcium
189 concentrations, despite depolarizing adrenal cells and stimulating aldosterone secretion (36).
190 Rather they induced increased intracellular acidification which is suggested to play a role in
191 regulating aldosterone biosynthesis in this context (Figure 1A) (36).
192 Mutations of PMCA3 are located in the transmembrane domain M4 and are all deletions of
193 multiple amino acids in the region between Leu425 and Leu433 (Table 2).
194 Electrophysiological and functional studies have shown that the p.Leu425_Val426del
195 mutation leads to reduced Ca^{2+} export due to loss of the physiological pump function and
196 increased Ca^{2+} influx due to opening of depolarization-activated Ca^{2+} channels. A Ca^{2+} leak
197 through the mutated pump has also been observed, inducing *CYP11B2* expression and
198 aldosterone biosynthesis (Figure 1A) (37).
199 Finally, *CACNA1D* mutations affect the function of the L-type Ca^{2+} channel α -subunit $\text{Ca}_v1.3$,
200 which is composed of four repeat domains (I to IV), each one consisting of six

201 transmembrane segments S1-S6 and a membrane associated loop between S5 and S6 (Table
202 2) (38). Whereas the S4 segments are involved in voltage sensing, the S5 and S6 domains as
203 well as the loop in between line the pore of the channel (39). 18 different *CACNAID*
204 mutations have been identified (25,26,30); they are gain-of-function mutations leading to a
205 shift of voltage-dependent channel activation towards more negative voltages, or to reduced
206 inactivation of the channel, followed by increased intracellular calcium concentrations with
207 induction of aldosterone biosynthesis (Figure 1A) (25,26).

208

209 **3.2. Genotype-phenotype correlations in APA**

210 *KCNJ5* mutations are the most frequent type of somatic mutation within APA (Table 1). Their
211 reported frequency ranges from 13-77%, with higher frequency in studies from Japan, China,
212 Korea and Taiwan (40-46). *CACNAID* mutations are the second most frequent mutations (up
213 to 10%), followed by *ATP1A1* and *ATP2B3*. Three studies have also explored *CTNNB1*
214 mutations, which are found in 2.1 – 5.1% of cases (26,28,29).

215 The correlations of clinical and molecular parameters with the mutation status are
216 heterogeneous among studies (Table 1). In a recent meta-analysis, Lenzini et al analyzed the
217 clinical correlates of *KCNJ5* mutations in 1636 patients from 13 studies (47). The overall
218 prevalence of *KCNJ5* mutations was 43%, ranging from 12-80% among different studies,
219 with a higher prevalence in studies from Japan and China compared to studies on populations
220 from Europe, US and Australia. Carriers of *KCNJ5* mutations were younger, more often
221 females, had larger tumors and had higher plasma aldosterone levels when compared to non-
222 carriers. No association was observed between the mutation status and systolic or diastolic
223 blood pressure and serum potassium levels overall, confirming previous results from the study
224 by Fernandes-Rosa et al (30). An association between the presence of *KCNJ5* mutations and
225 the lateralization index at adrenal vein sampling was described in two studies ((42,48)

226 , but not replicated in another study (49). In four studies, *KCNJ5* mutations were associated
227 with tumors composed mainly of large, lipid-laden cells resembling zona fasciculata cells
228 (Table 1). The other mutations were associated mainly with male sex and smaller tumors (25-
229 28,30,45,50), and the cellular phenotype of APA carrying *CACNAID*, *ATP1A1* or *ATP2B*
230 mutations was more heterogeneous than *KCNJ5* mutated tumors . Although few studies have
231 investigated *CTNNB1* mutations in large cohorts, they seem to be more prevalent in females
232 (26,28,29,51).

233

234 **3.3. Germline mutations in APA**

235 In addition to somatic mutations, the occurrence of germline *CACNAIH* (coding for the
236 voltage-dependent T-type calcium channel subunit alpha-1H) mutations, and rarely, germline
237 *KCNJ5* and *ARMC5* variants has been reported in PA (31,52,53). Daniil et al performed
238 whole exome sequencing in patients with different phenotypic presentations of PA, including
239 23 subjects with APA, 10 patients with a family history of PA and one subject with early-
240 onset PA. *CACNAIH* mutations were identified in early onset PA and patients with a family
241 history, and a germline *CACNAIH* p.Val1951Glu mutation was identified in one patient with
242 an APA (31). *CACNAIH* encodes the pore-forming $\alpha 1$ subunit of the T-type voltage-
243 dependent calcium channel Cav3.2, which has been implicated in membrane potential
244 oscillations in ZG cells (54). The variant is located in the C-terminal cytoplasmic domain of
245 Cav3.2, in a region possibly implicated in fast channel activation. Electrophysiological
246 investigation revealed a gain-of-function phenotype, whereby p.Val1951Glu induced a faster
247 recovery from inactivation and marked increase in voltage-dependent facilitation, two
248 properties which could favor larger calcium entry during repetitive electrical activity. In
249 H295R adrenocortical cells, transient transfection of the mutant channel led to an increase in
250 aldosterone biosynthesis and expression of *CYP11B2* (31).

251 Genetic abnormalities in APA driver genes are present as germline mutations in some familial
252 forms of PA, which account for 1 to 5% of cases and are transmitted as an autosomal
253 dominant trait. Although the terminology for FH is still evolving, to date four different forms
254 of familial hyperaldosteronism, FH-I to FH-IV, have been described. FH-I, resulting from the
255 formation of a chimeric gene between *CYP11B2* and *CYP11B1* (see above), is found in 0.5%
256 to 1.0% of cases of PA (55-57), but may represent up to 3% of cases in the paediatric
257 hypertensive population (58). FH-I is associated with BAH, but in rare cases adrenocortical
258 adenomas have been described. Heterozygous germline mutations in *KCNJ5* are found in FH-
259 III, a severe form of PA presenting in typical cases in childhood with severe hypertension and
260 profound hypokalemia, due to massive bilateral adrenal hyperplasia which requires bilateral
261 adrenalectomy to control the hypertension (24). In other cases, the disease is milder and with
262 normal appearing adrenals on imaging studies (59). Germline mutations in *CACNA1H* have
263 recently been identified as the cause of a new form of early onset PA associated or not with a
264 developmental disorder (31,60). In familial cases, the disease (named FH-IV) is transmitted as
265 an autosomal dominant trait. Similar mutations are also found in patients diagnosed as FH-II
266 with or without an adrenal adenoma as well as in APA (31). Finally, *de novo* germline
267 *CACNA1D* mutations have been described in a rare disease called PASNA (Primary
268 aldosteronism, seizures, neurological abnormalities), with no adrenal abnormality reported on
269 imaging (26).

270

271 **4. Pathological and genetic heterogeneity and the origin of APA**

272 While the functional link between mutations in driver genes in APA and aldosterone
273 production has been clearly demonstrated, the origin of APA in terms of increased cell
274 proliferation and nodule formation is not yet well understood, and work from different groups
275 has provided contradictory results on the sequence of events leading to aldosterone

276 overproduction and adenoma formation. Although the fact that familial forms of PA are due
277 to germline mutations in driver genes supports a role for these mutations in adrenal cortex cell
278 proliferation and nodulation, adrenal morphology is highly variable among these subjects.
279 Patients with FH-III harboring germline *KCNJ5* mutations may exhibit adrenal phenotypes
280 ranging from a normal adrenal to massive bilateral adrenal hyperplasia or adrenal nodules
281 (24,61,62). Similarly, patients carrying germline *CACNA1H* mutations show different adrenal
282 phenotypes including normal, hyperplastic and adenomatous adrenals
283 (31,60). No abnormality in adrenal morphology was observed in patients with PASNA
284 harboring germline *CACNA1D* mutations (26). *Ex vivo*, adrenocortical cells overexpressing
285 mutant *GIRK4* channels show increased intracellular Na⁺ concentration leading,
286 counterintuitively, to reduced cell proliferation and sodium-dependent apoptosis (33,35).
287 It has been previously shown that adrenals with APA exhibit adrenal cortex remodeling,
288 decreased vascularization, increased nodulation and ZG hyperplasia (63,64). These findings
289 suggest that adrenal cortex remodeling may precede APA development and that somatic
290 mutations in driver genes are secondary events specifying the pattern of hormone secretion. The
291 recent development of an aldosterone-synthase antibody (65) has allowed assessment of the
292 genetic and histological characteristics of adrenals with APA and has reinforced the hypothesis
293 of independent events leading to nodulation and aldosterone overproduction. Two studies in
294 particular have identified different genetic abnormalities in different aldosterone producing
295 nodules from the same adrenal. In one study, Dekkers et al analyzed 28 multinodular adrenals
296 and identified five adrenals with more than one nodule staining positively for aldosterone
297 synthase; in one adrenal two aldosterone-synthase positive nodules each harbored a different
298 *KCNJ5* mutation (66). In the second study, assessment of the *KCNJ5*, *ATP1A1*, *ATP2B3* and
299 *CACNA1D* mutation status in aldosterone synthase positive nodules from 27 multinodular
300 adrenals with APA identified 7 adrenals harboring different mutations between the principal

301 nodule and the secondary nodule within the same adrenal, including two adrenals with an APA
302 harboring a *CACNA1D* mutation and in one secondary nodule, a *KCNJ5* mutation (67). Further
303 studies extended the heterogeneity of aldosterone synthase expression to the APA itself, with
304 *KCNJ5* mutations only identified in APA regions positive for aldosterone synthase (68).
305 Finally, in a young PA patient with a germline *APC* mutation and a multinodular adrenal with
306 somatic biallelic inactivation of *APC*, we identified a somatic *KCNJ5* mutation in the nodule
307 expressing aldosterone synthase only (see below) (69). These data support a two-hit model for
308 APA formation whereby a specific genetic or epigenetic event is responsible for adrenal cortex
309 remodeling and nodule formation and somatic mutations in driver genes leading to excessive
310 aldosterone secretion represent second hits specifying the pattern of hormonal secretion (Figure
311 2).

312 A second model for the origin of APA has emerged from genetic studies performed on
313 aldosterone-producing cell clusters (APCC). APCC, which are found in normal adult adrenals
314 and in adrenals with APA, are composed by ZG-like cells expressing disabled 2 (*Dab2*, a
315 marker of ZG) in contact with the capsule and inner columnar *Dab2*-negative ZF-like cells,
316 which do not express *CYP11B1*, forming cords along sinusoids (70,71). APCC cells are
317 positive for *CYP11B2* and 3β HSD staining, but not for *CYP17*, consistent with their capacity
318 to synthesize aldosterone (70). Targeted next generation sequencing was performed on the
319 DNA of 23 APCC microdissected from adrenals from kidney transplant donors; somatic
320 mutations in *CACNA1D*, *ATP1A1* and *ATP2B3*, similar to those already described in APA, were
321 identified in 35% of APCC (72). The authors proposed that these findings are consistent with
322 the development of APA from APCC (Figure 2) and suggest different hypotheses for this
323 progression: single somatic mutations responsible for aldosterone production and cell
324 proliferation or second-hit mutations within the APCC leading to cell proliferation. In some
325 cases APCCs may represent terminal lesions not having the capacity to progress towards an

326 adenoma (72). Interestingly, no *KCNJ5* mutations, the most frequent genetic alteration
327 observed in APA, were identified in APCC. The authors suggest that this could be explained
328 by a rapid progression of *KCNJ5* mutated APCC to APA (72). Subsequently, *CACNA1D*
329 mutations were identified in 17 of 26 APCC from patients with lateralized PA negative for
330 detectable masses at imaging, suggesting that these lesions may contribute to PA in this
331 situation (73). Recently, a novel aldosterone-producing structure named a possible APCC-to-
332 APA transitional lesion (pAATL) was described in multinodular adrenals from two patients
333 with lateralized PA, which was suggested to be an intermediate lesion between APCC and APA
334 (74). While the APCC-like portion consists of a subcapsular ZG-like region and an inner ZF-
335 like region expressing CYP11B2 but not CYP11B1, the micro-APA-like portion is composed
336 of a heterogeneous mixture of CYP11B1-positive and CYP11B2-positive cells. Sequencing of
337 the known APA-associated mutations in three pAATL identified a *KCNJ5* mutation and an
338 *ATP1A1* mutation in the micro-APA-like portion of two pAATL, but not in their corresponding
339 APCC-like portions. The authors suggest that these data support the hypothesis that the micro-
340 APA derived from the APCC following the appearance of an APA driver mutation (74).
341 However, another pAATL carried two novel *ATP1A1* mutations in both the mAPA-like and
342 APCC-like portions, in this case supporting a clonal origin of the two portions (74). New
343 genetic studies in a larger number of normal and pathological adrenals with APCC are necessary
344 to clarify the relationship between these aldosterone-producing lesions and the origin of APA.

345

346 **5. Genetic abnormalities in Cortisol Producing Adenomas**

347 The genetics of CPA was unraveled in 2014 by the work of four independent groups
348 identifying somatic mutations of *PRKACA* as a cause of CS. Beuschlein and coworkers
349 performed WES in 10 paired adrenal tumor and germline DNA samples from patients with
350 CS, which revealed the presence of a recurrent somatic p.Leu206Arg mutation in the

351 *PRKACA* gene in 7 cases, with an additional p.Leu199_Cys200insTrp mutation in one case
352 (75). Sequencing of 129 additional samples identified the p.Leu206Arg mutation in 22 of 59
353 CPA (37%) from patients with overt CS, but not in tumors from 40 patients with subclinical
354 hypercortisolism (sCS), 20 APA, 20 non-functioning adenomas or 42 adrenocortical
355 carcinomas. Interestingly, among patients with different forms of bilateral adrenal hyperplasia
356 leading to CS, including bilateral micro- or macronodular hyperplasia, a germline copy-
357 number gain (duplication) of the genomic region on chromosome 19 that includes *PRKACA*
358 was identified in 5 patients from four kindreds. In one family with bilateral macronodular
359 hyperplasia, the genetic defect was transmitted in an autosomal dominant manner from the
360 mother to her affected child. The p.Leu206Arg mutation is located in the highly conserved
361 core of the interaction between the regulatory (RII β) and catalytic (C α) subunits of PKA. *In*
362 *vitro* studies demonstrated gain-of-function of the PKA catalytic subunit mutants with
363 impaired inhibition by the PKA regulatory subunit, and increased protein expression of the
364 PKA catalytic subunit in cells from patients with germline chromosomal gains, with both
365 mechanisms leading to increased PKA activity. Basal PKA activity in cells transfected with
366 mutant C α subunits was increased and was not reduced by excess nonmutant RII β subunit
367 expression, nor was it responsive to cAMP analogues, indicating that the mutations made the
368 catalytic subunit resistant to the physiological suppression. The presence of *PRKACA*
369 mutations was associated with a more severe phenotype in patients with overt CS and
370 *PRKACA* mutation carriers had significantly increased expression of *MC2R*, *StAR*, *CYP21A1*,
371 *HSD3B2* and *CYP11A1* mRNA in adrenal tumors. These results were confirmed in the three
372 other studies. By performing WES in 25 tumor samples producing excess cortisol, including
373 22 CPA and 3 ACC, Goh et al identified six cases carrying the recurrent p.Leu206Arg
374 substitution (76). Six cases had gain-of-function mutations in *CTNNB1* and two cases in
375 *GNAS* (coding for G α s), with *PRKACA*, *GNAS* and *CTNNB1* mutations being mutually

376 exclusive. Additional targeted sequencing in 38 patients identified the p.Leu206Arg
377 substitution collectively in 13 out of 63 tumors representing 24% of all ACA and 35% of all
378 ACA associated with overt CS. In this study, adenomas carrying *PRKACA* or *GNAS*
379 mutations were significantly smaller than those without these mutations, and the patients were
380 of younger age at diagnosis with overt CS. WES also revealed a group of tumors harboring
381 many somatic copy number variants with frequent deletion of *CDC42* and *CDKN2A*,
382 amplification of 5q31.2 and protein-altering mutations in *TP53* and *RBI*. This mutational
383 spectrum is more similar to that of malignant tumors, indicating that they may have greater
384 malignant potential or represent early steps towards the development of ACC.

385 A higher rate of somatic *PRKACA* mutations seems to occur in subjects with an Asian
386 ancestry. Cao et al (77) reported the occurrence of the p.Leu205Arg mutation (equivalent to
387 the p.Leu206Arg mutation in the other reports) in 65.5% of a total of 87 CPA from China
388 screened by WES and targeted sequencing. In this study, there was no significant correlation
389 between the mutation status and clinical or biological parameters. The authors also identified
390 one somatic *PRKARIA* mutation, one *CTNNB1* mutation, a truncating *APC* mutation and two
391 activating *GNAS* mutations in CPA; an additional *CTNNB1* mutation was found in an adrenal
392 oncocytoma (a very rare form of cortisol producing adrenal tumor). The authors also
393 identified the recurrently mutated gene *DOTIL* coding for a histone H3 methyltransferase as
394 well as one *HDAC9* mutation in ACTH-independent macronodular adrenocortical hyperplasia
395 (AIMAH), suggesting involvement of chromatin deregulation, and *CLASP2* mutations in 2 of
396 three adrenocortical oncocytomas. RNA-sequencing data comparing *PRKACA* mutated and
397 non-mutated tumors identified 232 differentially expressed genes, with significant enrichment
398 of gene ontology terms “biosynthesis and metabolism of steroid and cholesterol” and
399 “response to chemical stimulus”, with increased expression of the genes *StAR*, *MC2R*,
400 *GSTAI*, *CXCL2*, and *S100A8/9*.

401 Finally, in a Japanese cohort, 50% of cases (4/8) with adrenocortical adenomas associated
402 with corticotropin-independent Cushing's syndrome were carriers of the *PRKACA*
403 p.Leu206Arg mutation (78). An additional patient carried a recurrent p.Arg201Cys *GNAS*
404 mutation. Follow-up sequencing in an additional 57 cases identified the *PRKACA*
405 p.Leu206Arg mutation in 30 cases and *GNAS* mutation in 10 cases, representing a total of
406 52.3% and 16.9% of mutational events and which were mutually exclusive. These mutations
407 were found in 76% of patients with overt CS; interestingly, two patients with sCS were also
408 carriers of a *PRKACA* and a *GNAS* mutation. In this study, carriers of the recurrent *PRKACA*
409 p.Leu206Arg mutation, but also those with *GNAS* mutations had higher cortisol levels after an
410 overnight dexamethasone suppression test and smaller adenoma size, suggesting a higher
411 cortisol output compared to non-mutated tumors.

412 After these seminal works, a similar prevalence of *PRKACA* mutations was found in different
413 cohorts of CS patients from different countries (Table 3). The largest study published to date
414 was performed within the ENS@T and included 149 samples from nine different European
415 centers, among which were 64 CPA from patients with overt CS, 36 CPA samples from
416 patients with sCS, 32 nonsecreting adenomas, 4 androgen producing tumors, 5 ACC and 8
417 samples from PBMAH. Heterozygous somatic *PRKACA* mutations were found in 22/64
418 samples from patients with overt CS (34%). 18 patients carried the recurrent p.Leu206Arg
419 mutation, while a new mutation p.Cys200_Gly201insVal was identified in three patients and a
420 p.Ser213Arg+p.Leu212_Lys214insIle-Ile-Leu-Arg mutation was identified in one patient.

421 These newly identified mutations involved a region implicated in the interaction between the
422 PKA regulatory and catalytic subunits. As in previous studies, patients with *PRKACA*
423 mutations showed more severe cortisol abnormalities (higher levels of cortisol after an
424 overnight dexamethasone suppression test) and smaller adenoma size compared with non-
425 carriers (75,76). In a study exploring 60 patients with overt (n=36) or subclinical (n=24) CS,

426 Thiel et al (79) identified the recurrent somatic *PRKACA* p.Leu206Arg mutation in 23.1% of
427 tumors, somatic *CTNNB1* mutations (p.Ser45Pro, p.Ser45Phe) in 23.1%, the recurrent *GNAS*
428 p.Arg201Cys mutation in 5.8%, and a double mutation of *CTNNB1* and *GNAS* in one case.
429 *PRKACA* and *GNAS* mutations were again mutually exclusive. In one patient with unilateral
430 hyperplasia, a somatic *PRKACA* p.Leu206Arg mutation was identified, while patients with
431 bilateral adenomas did not have known somatic mutations. The presence of *PRKACA*
432 mutations was associated with younger age, overt Cushing's syndrome, and higher cortisol
433 levels after an overnight dexamethasone suppression test compared with non-*PRKACA*-
434 mutant or *CTNNB1*-mutant lesions (79). Lastly, targeted genetic screening for *GNAS*,
435 *PRKACA*, and *KCNJ5* mutations in Japanese patients, 15 with CS, 9 with sCS, and 33 with
436 an APA, found mutations in the *PRKACA* gene in 4 (26%) patients with CS, while mutations
437 in the *GNAS* gene were detected in 2 (13%). A mutation in the *GNAS* gene was detected in 1
438 patient with sCS (80,81).

439 Altogether, more than 580 patients with CPA or hyperplasia have been investigated. Somatic
440 *PRKACA* mutations were found in 28%, *CTNNB1* mutations in 4%, and *GNAS* mutations in
441 4% of cases (Table 3). *PRKACA* mutations were associated with overt CS, more severe
442 cortisol abnormalities and smaller tumors. The question as to whether other recurrent
443 mutations or genetic abnormalities are found in CPA has been addressed by Ronchi et al, who
444 performed WES in 99 patients with ACA, including 74 CPA and 25 non-functioning
445 adenomas negative for *PRKACA* mutations (82). Different mutations affecting genes of the
446 cAMP/PKA and Wnt/ β -catenin signalling pathway were identified (Figure 1B and 1C), the
447 latter are more frequently associated with larger tumors and endocrine inactivity. Genetic
448 variants were also identified in genes belonging to the calcium signalling pathway. To what
449 extent these single variants are causative for cortisol production and/or adenoma formation
450 remains to be established.

451

452 **6. Genetics of aldosterone and cortisol co-secretion**

453 Co-secretion of aldosterone and cortisol has been described in several reports and biochemical
454 abnormalities of cortisol excess in PA have been associated with worse cardiovascular
455 outcomes compared to APA without cortisol secretion (83). Recent studies suggest that
456 cortisol excess may be more frequent in patients with APA than previously thought.
457 Histological examination of adrenals with APA has consistently shown co-expression of
458 CYP11B2 and CYP11B1 in a number of cases (84).

459 A Japanese study explored somatic *GNAS*, *PRKACA*, and *KCNJ5* mutations in 15 patients
460 with CS, 9 patients with sCS, and 33 patients with APA (80,81) (Table 4). From 33 APA
461 tested, 10 had autonomous cortisol secretion based on an overnight dexamethasone
462 suppression test, increased midnight cortisol and/or decreased plasma ACTH levels.

463 Mutations in the *PRKACA* gene were found in 4 (26%) patients with CS, while mutations in
464 the *GNAS* gene were detected in 2 (13%). Mutations in the *GNAS* gene were also detected in 1
465 patient (11%) with sCS. Twenty-four patients with APA (72%) harboured *KCNJ5* mutations.

466 Among APA patients with autonomous cortisol secretion, six carried a somatic *KCNJ5*
467 mutation, while two had a somatic *GNAS* mutation. *KCNJ5* and *GNAS* mutations in APA
468 were mutually exclusive. No *PRKACA* mutations were identified in patients with APA (80).

469 In another study, the same authors identified a *KCNJ5* mutation in 2 out of 3 patients with
470 APA and sCS (85).

471 In a study exploring 60 patients with cortisol excess, Thiel et al identified 4 cases with
472 aldosterone co-secretion, 2 with overt and 2 with subclinical CS. Among those, 2 were
473 carriers of mutations in *KCNJ5* (79). Finally, Rhayem et al identified somatic *PRKACA*
474 mutations in two patients diagnosed with PA, a newly identified p.His88Asp variant and the

475 recurrent p.Leu206Arg mutation (32). The patient with the recurrent p.Leu206Arg had
476 biochemical CS, while the carrier of the p.His88Asp variant had normal cortisol levels.
477 A distinct histopathological entity is the adrenal harboring two nodules each one secreting a
478 different hormone. Fallo and coworkers have investigated the occurrence of concurrent PA
479 and subclinical cortisol hypersecretion in a prospective series of 76 consecutive patients with
480 PA (86). Three out of 76 patients failed to appropriately suppress cortisol after an overnight
481 dexamethasone suppression test; one of them also showed suppressed ACTH levels and
482 mildly elevated urinary cortisol excretion. The resected adrenal showed a 4-cm nodule
483 expressing *CYP11B1* by *in-situ* hybridization, whereas *CYP11B2* expression was restricted to
484 the peritumoral region composed of zona glomerulosa-like cells, suggesting the co-existence
485 of a cortisol-producing adenoma and an aldosterone-producing hyperplasia in the same
486 adrenal. Namba et al described a patient with lateralized PA and CS, in whom examination of
487 the adrenal revealed two distinct nodules, one expressing CYP11B1 and carrying a
488 p.Leu206Arg *PRKACA* mutation, while the other nodule expressed CYP11B2 and carried a
489 somatic *KCNJ5* mutation (87).

490 Altogether these studies raise a certain number of questions about the histological, cellular
491 and genetic nature of adrenal lesions producing aldosterone and cortisol. In particular, they
492 emphasize the need to explore the common pathways leading to APA and CPA in terms of
493 signals triggering cell proliferation and/or defining hormonal output.

494

495 **7. Common hits for APA and CPA**

496 **7.1. The role of the Wnt/ β -catenin pathway in adrenal tumorigenesis**

497 The role of the Wnt/ β -catenin pathway has emerged as crucial in adrenal development and
498 disease. β -catenin, as well as ARMC5 (Armadillo repeat-containing protein 5, see below), are
499 both members of the Armadillo repeat containing (ARMC) gene family. Armadillo repeats are

500 approximately 40 amino acid long tandemly repeated domains which usually fold together to
501 form a single, rigid protein domain called the armadillo (ARM) domain. β -catenin is a key
502 downstream component of the canonical Wnt signaling pathway. In the absence of Wnt
503 ligand, β -catenin is in complex with AXIN1, AXIN2, APC, CSNK1A1 and GSK3B, which
504 promotes its phosphorylation on N-terminal Ser and Thr residues, ubiquitination and
505 subsequent degradation by the proteasome. In the presence of Wnt ligand, the complex is
506 disrupted and β -catenin accumulates in the nucleus, where it acts as a coactivator for
507 transcription factors of the TCF/LEF family, leading to transcriptional regulation of Wnt
508 responsive genes.

509 Modulation of different components of the Wnt/ β -catenin pathway in mice leads to adrenal
510 abnormalities. In the absence of Wnt4, one of the main ligands of the Wnt/ β -catenin pathway,
511 mice die immediately after birth due to organ defects such as kidney dysfunction or poor
512 pituitary gland development. Despite normal adrenal morphology, Wnt4 knockout animals
513 produce less aldosterone due to decreased expression of *cyp11b2* and show reduced
514 expression of other markers of ZG cells, suggesting a defect in ZG development in the
515 absence of Wnt4 (88). As observed in mice, loss of function mutations of WNT4 in humans
516 lead to dysgenesis of the kidneys and to female and male sex reversal; adrenal development
517 and external genitalia are also affected in human fetuses (89). Along the same lines, the
518 targeted disruption of β -catenin restricted to sf-1 expressing cells (adrenal cortex, somatic
519 cells of the gonads, spleen, pituitary gonadotropes and ventromedial hypothalamic nucleus
520 (90) leads to complete adrenal aplasia when β -catenin is totally absent during development
521 and to a defect in the maintenance of adrenocortical tissue due to increased apoptosis in adult
522 mice when the level of expressed β -catenin is low (91). In H295R cells, a human
523 adrenocortical cell line with activating *CTNNB1* mutations, a decrease in β -catenin expression
524 induces cell cycle arrest, changes in cell morphology, modification of the expression of

525 epithelial to mesenchymal transition markers and a modification of cell motility (92).

526 Whereas these results highlight the central role of β -catenin in adrenal development, tight
527 regulation of its activation is also crucial. Mice carrying a heterozygous mutation of APC,
528 leading to the formation of a truncated protein and constitutive β -catenin activation, exhibit
529 multiple intestinal tumors. In addition these mice also develop hyperaldosteronism,
530 hypervolemia and increased blood pressure, but their adrenal phenotype has not been explored
531 (93,94). Mice expressing a constitutively active β -catenin in the adrenal cortex exhibit
532 progressive adrenal hyperplasia and dysplasia leading, with time, to the formation of nodules
533 in both cortex and medulla; abnormal vascularization was also observed, and in later stages in
534 rare cases, development of adrenal carcinoma (95). In humans, activation of β -catenin,
535 demonstrated by its cytoplasmic and/or nuclear accumulation, was found in a large number of
536 adrenocortical tumors, including adrenocortical adenomas (71,96-98). Mutations in the
537 *CTNNB1* gene, leading to constitutive activation of β -catenin were found in both malignant
538 and benign tumors (Figure 1C) (96,97). In benign tumors, the presence of β -catenin mutations
539 was found to be associated with larger adenomas and absence of hormonal secretion (97). In
540 hormonally active ACA, the prevalence of *CTNNB1* mutations is estimated between 2 to 5%
541 in APA (28,29,99) and \approx 4% in CPA (see previous sections). The presence of *CTNNB1*
542 mutations in APA was not associated with a particular histological or morphological
543 phenotype, but seems to be more prevalent in females (26,28,29,51). In addition, Teo and co-
544 workers reported three women with PA, harboring *CTNNB1* mutations in their adenoma that
545 were associated with aberrant expression of G-protein coupled receptors (GPCR), two during
546 pregnancy and one after menopause (51), suggesting a possible acceleration of the disease
547 during pregnancy and menopause due to high gonadotropin levels acting on aberrantly
548 expressed gonadotropin receptors. Since *CTNNB1* mutations were also reported in non-
549 pregnant women (28,29) and men, the relation between *CTNNB1* mutations and pregnancy

550 and the possible interaction with aberrant gonadotropin receptors remain to be further
551 clarified (100,101).

552 The role of the Wnt β -catenin pathway in the development of APA is further supported by the
553 case of a young patient who was diagnosed with severe arterial hypertension due to primary
554 aldosteronism at age 26, followed by hemorrhagic stroke four years later, due to lateralized
555 aldosterone secretion from an APA in the context of bilateral multinodular adrenal glands
556 (69). The patient, in whom additional exploration identified asymptomatic Familial
557 Adenomatous Polyposis (FAP) associated with a heterozygous germline *APC* mutation,
558 showed biallelic *APC* inactivation due to loss of heterozygosity in two adrenal nodules. The
559 aldosterone producing nodule carried an additional somatic *KCNJ5* mutation supporting a
560 two-hit model for APA development (69). This patient also had incomplete cortisol
561 suppression after an overnight dexamethasone suppression test, but normal 24-h urinary free
562 cortisol, maintained circadian rhythm of cortisol secretion and normal ACTH levels;
563 *CYP11B1* expression was detected in all adrenal nodules, including the one carrying the
564 *KCNJ5* mutation (unpublished).

565 Remarkably, a link between the Wnt/ β -catenin and the PKA pathway has recently been
566 established, showing that activation of PKA prevents zona glomerulosa differentiation
567 through WNT4 repression and Wnt pathway inhibition, suggesting that PKA activation in the
568 zona fasciculata is a key driver of Wnt inhibition and lineage conversion. (102).

569

570 **7.2. ARMC5 mutations in adrenocortical tumors**

571 Evidence that ARMC5 is involved in adrenal tumorigenesis came from recent studies
572 exploring PBMAH (also called ACTH-independent macronodular adrenal hyperplasia or
573 AIMAH). PBMAH is a form of macronodular adrenal hyperplasia characterized by multiple,

574 bilateral, non-pigmented, benign, adrenocortical nodules. It results in excessive production of
575 cortisol leading to ACTH-independent overt or subclinical Cushing syndrome (103).
576 Germline *ARMC5* mutations were identified in familial cases and are present in 50% of
577 apparently sporadic cases. Somatic events occur independently in adrenal nodules, suggesting
578 that *ARMC5* acts as a tumor suppressor gene (103).

579 A recent study has shown that PBMAH is not truly ACTH-independent since
580 proopiomelanocortin expression was described in clusters of steroidogenic cells in PBMAH
581 tissue, suggesting local ACTH production with paracrine regulation of cortisol biosynthesis
582 (104). The existence of heterogeneous phenotypes (105), such as that observed in a Brazilian
583 family with adrenal macronodular disease showing bilateral and unilateral adrenal nodules, has
584 highlighted the complexity of the condition, leading some authors to prefer the name primary
585 macronodular adrenal hyperplasia (PMAH) (106). PBMAH is usually diagnosed after the
586 investigation of an adrenal incidentaloma or by the presence of overt CS, although insidious or
587 mild CS is more frequent (107,108). Aldosterone secretion was also described in patients with
588 PBMAH (69,109,110). Previous studies have demonstrated that cortisol secretion in PBMAH
589 may be regulated by various hormones via aberrant adrenal expression of several G-protein-
590 coupled receptors (107,111,112). Illegitimate G-protein-coupled receptors expressed in
591 PBMAH include the gastric inhibitory polypeptide (GIP) receptor, vasopressin receptors, β -
592 adrenergic receptors, LH/hCG receptors, and the serotonin 5-HT₄ and 5-HT₇ receptors ((107)
593 and references therein).

594 Although sporadic forms appear to be more frequent, the description of familial forms and the
595 occurrence of bilateral adrenal lesions support a genetic cause for PBMAH. Recently, combined
596 SNP array and microsatellite marker analysis have shown a somatic 16p11 loss of
597 heterozygosity (LOH) in 8 of 33 tumor samples from patients with PBMAH. In parallel, WES
598 analysis followed by direct sequencing of blood and tumor samples has identified somatic

599 mutations in *ARMC5*, the armadillo repeat containing 5 gene mapped to 16p11.2, in 18 of 33
600 PBMAH patients (113). All patients carried a germline *ARMC5* mutation and a second somatic
601 *ARMC5* event in the tumor DNA, including LOH, a second mutation or microdeletion,
602 suggesting a 2-hit model for the development of PBMAH (113). Interestingly, distinct somatic
603 *ARMC5* alterations are observed in different nodules from the same adrenal (113), exemplified
604 by an emblematic case of 16 different somatic *ARMC5* mutations in 20 adrenal nodules from
605 the same patient (114).

606 The function of *ARMC5* is unknown and no other diseases have been associated with mutations
607 in this gene. *ARMC5* encodes a 935 amino acid protein of the armadillo repeat family containing
608 an armadillo repeat domain in the N-terminal region and a BTB/POZ in the C-terminal region
609 (115). Analysis of the expression of four *ARMC5* isoforms in 46 human tissues has shown that
610 at least one *ARMC5* isoform is ubiquitously expressed throughout the body, but only seven
611 tissues expressed all four isoforms, including the adrenal gland (116). *Armc5* knockout mice
612 have defective development and immune responses, with adrenal hyperplasia in old animals
613 (117). Transfection of wild-type *ARMC5* in H295R cells induces apoptosis, which is not
614 observed when mutant *ARMC5* are transfected. Furthermore, silencing of *ARMC5* in H295R
615 cells reduced the expression of the steroid enzymes *CYP17A1* and *CYP21A2*; *NR5A1* and
616 *MC2R*, as well as cortisol production (113). PBMAH patients with *ARMC5* mutations show
617 more overt CS than patients without *ARMC5* mutations (113,118). In a cohort of 98 unrelated
618 PBMAH subjects, *ARMC5* mutations were found in 24 patients (26%). Patients with *ARMC5*
619 mutations again showed more frequently overt CS and had larger adrenals with a higher number
620 of nodules than non-mutated patients (119). These results were confirmed in an Italian cohort
621 of PBMAH patients, in which *ARMC5* mutated patients exhibited higher cortisol levels, more
622 severe hypertension and diabetes, and larger adrenal lesions (120). *ARMC5* mutations have also
623 been identified in familial forms of PBMAH (105,121-123). In one Brazilian family with

624 PBMAH, a germline *ARMC5* mutation was found which segregated with the disease, although
625 the clinical phenotype and adrenal involvement (unilateral or bilateral) were variable among
626 carriers (105). In five families with PBMAH, Gagliardi et al have found germline *ARMC5*
627 mutations in four families with CS and no *ARMC5* mutation in one family with PA and sCS
628 (121). Interestingly, in a large French-Canadian PBMAH family, *ARMC5* mutations were found
629 in affected subjects together with aberrant expression of β -adrenergic and V1-vasopressin
630 receptors in adrenal nodules (123). In this case, the aberrant expression of GPCR may represent
631 a secondary event in the development of PBMAH, but the link between *ARMC5* mutations and
632 this pattern of receptor expression is not yet clarified.

633 Zilbermint et al have sequenced *ARMC5* in germline DNA from 56 subjects with PA and have
634 identified 12 heterozygous variants, 9 missense variants and three variants leading to alternative
635 splicing (124). *In silico* analysis of the *ARMC5* variants has shown that six variants were
636 predicted to be damaging, including the *ARMC5* variant p.R898W, which was previously
637 described in one patient with PBMAH (118), and a novel missense mutation *ARMC5* p.P826H
638 (124). All carriers of these variants were African-American, two had bilateral macronodular
639 hyperplasia, and tumor DNA sequencing showed neither additional somatic *ARMC5* mutations
640 nor *ARMC5* loss of heterozygosity. APA with predicted damaging *ARMC5* variants exhibit
641 lower *ARMC5* expression than the adjacent adrenal cortex. The functional consequences of
642 these *ARMC5* variants are not completely understood. Silencing of *ARMC5* in H295R cells
643 leads to decreased *CYP11B2* expression, and therefore a reduction of the aldosterone-secretory
644 capacity. The authors suggest that the higher aldosterone secretion in PA patients carrying
645 *ARMC5* variants may be explained by the increased adrenocortical mass, similar to what was
646 observed in patients with PBMAH and hypercortisolism (124). An association of *ARMC5*
647 mutations with PA was not replicated in an Italian study assessing the presence of *ARMC5*
648 mutations in 39 PA patients with bilateral computed tomography-detectable adrenal alterations,

649 from which 8 had unilateral and 27 bilateral aldosterone secretion (125). Different *ARMC5*
650 variants were identified in 18 subjects, among them 11 common variants, two rare ones and two
651 previously unreported variants were found, but *in silico* analysis did not identify possibly
652 damaging *ARMC5* variants (125). These contradictory data do not allow confirmation of the
653 role of *ARMC5* mutations in PA and further studies are required to better understand the role of
654 *ARMC5* in the development of adrenal nodules and aldosterone excess.

655

656 **7.3. Germline mutations associated with ACA and macronodular hyperplasia**

657 Genetic alterations leading to multiple tumor syndromes and mutations affecting genes of the
658 cAMP/PKA signaling pathway have been associated with PBMAH (review in (106,108)).
659 Familial adenomatous polyposis (FAP) is a disease characterized by multiple colonic polyps
660 with an increased risk of colon carcinomas, due to an inactivating germline mutation of *APC*
661 and a somatic second hit (mutation or LOH), resulting in constitutive activation of the Wnt/ β -
662 catenin pathway (126). Adrenal masses are more frequently found in patients with FAP than in
663 the general population (127), including non-functioning adrenal adenomas, adrenocortical
664 cancers, and PBMAH (128,129). Multiple endocrine neoplasia type 1 (MEN1) is an autosomal
665 dominant syndrome resulting from inactivating mutations in the *MEN1* gene, which is
666 characterized by the development of multiple endocrine and non-endocrine tumors, most
667 frequently hyperparathyroidism, pituitary adenomas, and pancreatic neuroendocrine tumors
668 (130). MEN1 encodes the protein menin which has a role in the regulation of cell cycle, cell
669 growth and proliferation (131). The analysis of adrenal involvement in 715 patients with MEN1
670 has shown adrenal tumors (>10mm in size) in 10% of the cohort; in 19.4% of these cases the
671 tumors were bilateral, and in 12.5% of the cases the tumors were >40mm in size (132). A *MEN1*
672 mutation was also identified in one patient with PBMAH and hyperparathyroidism, without a
673 family history or other endocrine abnormalities (129). In addition, LOH at the MEN1 locus was

674 also reported in APA (133). Another hereditary disease associated with PBMAH is the
675 hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC), a disease caused by
676 germline mutations in the fumarate hydratase (FH) gene (134). Adrenal lesions are found in
677 7.8% of patients with HLRCC, including bilateral lesions associated with ACTH-independent
678 hypercortisolism (135), and germline FH mutations were identified in patients with PBMAH
679 associated with HLRCC (129,134). Genetic alterations leading to activation of cAMP/PKA
680 signaling were also described in patients with PBMAH. Post-zygotic somatic mutations in the
681 gene encoding the alpha subunit of stimulatory G protein (*GNAS*), leading to constitutive
682 activation of adenylate cyclase, result in McCune Albright syndrome, which is characterized
683 by a triad constituted by polyostotic fibrous dysplasia, cafe' au lait skin spots, and gonadotropin-
684 independent precocious puberty, associated with other endocrine and non-endocrine diseases,
685 including CS (136). Somatic *GNAS* mutations were described in a few cases of PBMAH
686 without other typical signs of McCune Albright syndrome and might represent variants of this
687 syndrome (129,137). In isolated cases, variants in *PDE11A*, encoding the isoform 11A of the
688 phosphodiesterase enzyme, and in *MC2R* were associated with PBMAH (138-140). Finally,
689 duplication of a genomic region of chromosome 19 including *PRKACA* was also identified in
690 patients with PBMAH (75,141).

691

692 **8. Concluding remarks**

693 Over the past few years, extraordinary progress has been made in our understanding of the
694 genetic abnormalities leading to APA and CPA. While genetic testing in inherited forms of
695 the diseases has been translated into clinical practice, and family screening is useful for
696 management of affected family members, the clinical utility of diagnosing somatic mutations
697 is difficult to anticipate from available studies on genotype-phenotype correlations and
698 outcome. Ideally, identification of mutations prior to surgery, through the application of

699 surrogate biomarkers or genetic testing on circulating cell-free DNA, could guide treatments
700 to specifically target mutated proteins, as shown for APA (142,143). There seems to be an
701 overlap of genetic abnormalities leading to different endocrine abnormalities in ACA. In
702 particular, *CTNNB1* mutations are found at relatively high frequency (at least comparable to
703 what observed for *ATP1A1* or *ATP2B3* mutations in APA) in CPA but also usually in APA.
704 Furthermore, genetic variants affecting genes of the calcium signaling pathway are enriched
705 in WES data from CPA, suggesting that calcium, in addition to PKA signaling, may lead to
706 autonomous cortisol overproduction. This is not surprising, as a subset of APA show some
707 cortisol co-secretion, or biochemical glucocorticoid abnormalities (144), and in some cases
708 those tumors harbor somatic *KCNJ5* mutations. In addition, overexpression of mutated
709 *GIRK4* channels in HAC15 cells not only increases *CYP11B2* expression but also *CYP11B1*
710 (33). Future studies need to address the sequence of events leading to adrenal cell
711 proliferation, nodule formation and specification of the hormonal secretory pattern. It will be
712 of particular interest to explore whether common susceptibility alleles or rare variant may
713 predispose to the development of APA and CPA.

714

715

716

717 **References**

718

- 719 **1.** Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered
720 adrenal masses. *Endocr Rev.*1995; 16:460-484
- 721 **2.** Missaghian E, Kempna P, Dick B, Hirsch A, Alikhani-Koupaei R, Jegou B, Mullis
722 PE, Frey BM, Fluck CE. Role of DNA methylation in the tissue-specific expression of
723 the CYP17A1 gene for steroidogenesis in rodents. *J Endocrinol.*2009; 202:99-109
- 724 **3.** Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A
725 chimaeric 11beta-hydroxylase aldosterone synthase gene causes glucocorticoid-
726 remediable aldosteronism and human hypertension. *Nature.*1992; 355:262-265
- 727 **4.** Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial
728 varieties. *J Hypertens.*2000; 18:1165-1176
- 729 **5.** Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion
730 and low plasma renin activity relieved by dexamethasone. *Can Med Assoc J.*1966;
731 95:1109-1119
- 732 **6.** New M. Hypertension of childhood with suppressed renin. *Endocr Rev.*1980; 1:421-
733 430
- 734 **7.** Connell JM, Davies E. The new biology of aldosterone. *J Endocrinol.*2005; 186:1-20
- 735 **8.** Bandulik S, Penton D, Barhanin J, Warth R. TASK1 and TASK3 potassium channels:
736 determinants of aldosterone secretion and adrenocortical zonation. *Horm Metab*
737 *Res.*2010; 42:450-457
- 738 **9.** Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in
739 cellular signaling pathways. *Physiol Rev.*2004; 84:489-539
- 740 **10.** Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase
741 expression. *Mol Cell Endocrinol.*2004; 217:67-74

- 742 **11.** Ruggiero C, Lalli E. Impact of ACTH Signaling on Transcriptional Regulation of
743 Steroidogenic Genes. *Front Endocrinol (Lausanne)*.2016; 7:24
- 744 **12.** Vinson GP. Functional Zonation of the Adult Mammalian Adrenal Cortex. *Frontiers*
745 *in neuroscience*.2016; 10:238
- 746 **13.** Lefebvre H, Duparc C, Prevost G, Zennaro MC, Bertherat J, Louiset E. Paracrine
747 control of steroidogenesis by serotonin in adrenocortical neoplasms. *Mol Cell*
748 *Endocrinol*.2015; 408:198-204
- 749 **14.** Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M,
750 Young WF, Jr. The Management of Primary Aldosteronism: Case Detection,
751 Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. *J Clin*
752 *Endocrinol Metab*.2016; 101:1889-1916
- 753 **15.** Hannemann A, Wallaschofski H. Prevalence of primary aldosteronism in patient's
754 cohorts and in population-based studies--a review of the current literature. *Horm*
755 *Metab Res*.2012; 44:157-162
- 756 **16.** Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C,
757 Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ,
758 Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E,
759 Boscaro M, Pessina AC, Mantero F. A prospective study of the prevalence of primary
760 aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol*.2006; 48:2293-2300
- 761 **17.** Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P.
762 Hyperaldosteronism among black and white subjects with resistant hypertension.
763 *Hypertension*.2002; 40:892-896
- 764 **18.** Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated
765 with primary aldosteronism: a controlled cross-sectional study. *Hypertension*.2013;
766 62:331-336

- 767 **19.** Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V,
768 Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular
769 events in patients with primary aldosteronism. *J Clin Endocrinol Metab.*2013;
770 98:4826-4833
- 771 **20.** Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario
772 M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E,
773 Pessina AC, Mantero F. Renal damage in primary aldosteronism: results of the PAPY
774 Study. *Hypertension.*2006; 48:232-238
- 775 **21.** Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC.
776 Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma.
777 *Circulation.*1997; 95:1471-1478.
- 778 **22.** Freel EM, Mark PB, Weir RA, McQuarrie EP, Allan K, Dargie HJ, McClure JD,
779 Jardine AG, Davies E, Connell JM. Demonstration of blood pressure-independent
780 noninfarct myocardial fibrosis in primary aldosteronism: a cardiac magnetic resonance
781 imaging study. *Circ Cardiovasc Imaging.*2012; 5:740-747
- 782 **23.** Amar L, Baguet JP, Bardet S, Chaffanjon P, Chamontin B, Douillard C, Durieux P,
783 Girerd X, Gosse P, Hernigou A, Herpin D, Houillier P, Jeunemaitre X, Joffre F,
784 Kraimps JL, Lefebvre H, Menegaux F, Mounier-Vehier C, Nussberger J, Pagny JY,
785 Pechere A, Plouin PF, Reznik Y, Steichen O, Tabarin A, Zennaro MC, Zinzindohoue
786 F, Chabre O. SFE/SFHTA/AFCE primary aldosteronism consensus: Introduction and
787 handbook. *Ann Endocrinol (Paris).*2016; 77:179-186
- 788 **24.** Choi M, Scholl UI, Yue P, Bjorklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y,
789 Patel A, Men CJ, Lolis E, Wisgerhof MV, Geller DS, Mane S, Hellman P, Westin G,
790 Akerstrom G, Wang W, Carling T, Lifton RP. K⁺ channel mutations in adrenal

791 aldosterone-producing adenomas and hereditary hypertension. *Science*.2011; 331:768-
792 772

793 **25.** Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S,
794 Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers
795 T, Tops B, Kusters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass
796 F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS,
797 Striessnig J, Nissen P, Brown MJ. Somatic mutations in ATP1A1 and CACNA1D
798 underlie a common subtype of adrenal hypertension. *Nat Genet*.2013; 45:1055-1060

799 **26.** Scholl UI, Goh G, Stolting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL,
800 Korah R, Starker LF, Kunstman JW, Prasad ML, Hartung EA, Mauras N, Benson MR,
801 Brady T, Shapiro JR, Loring E, Nelson-Williams C, Libutti SK, Mane S, Hellman P,
802 Westin G, Akerstrom G, Bjorklund P, Carling T, Fahlke C, Hidalgo P, Lifton RP.
803 Somatic and germline CACNA1D calcium channel mutations in aldosterone-
804 producing adenomas and primary aldosteronism. *Nat Genet*.2013; 45:1050-1054

805 **27.** Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD,
806 Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T,
807 Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F,
808 Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B,
809 Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3
810 lead to aldosterone-producing adenomas and secondary hypertension. *Nat Genet*.2013;
811 45:440-444, 444e441-442

812 **28.** Scholl UI, Healy JM, Thiel A, Fonseca AL, Brown TC, Kunstman JW, Horne MJ,
813 Dietrich D, Riemer J, Kucukkoylu S, Reimer EN, Reis AC, Goh G, Kristiansen G,
814 Mahajan A, Korah R, Lifton RP, Prasad ML, Carling T. Novel Somatic Mutations in

- 815 Primary Hyperaldosteronism are related to the Clinical, Radiological and Pathological
816 Phenotype. *Clin Endocrinol (Oxf)*.2015;
- 817 **29.** Akerstrom T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A, Stalberg P,
818 Robinson B, Alexander Iwen K, Dralle H, Walz MK, Lehnert H, Sidhu S, Gomez-
819 Sanchez C, Hellman P, Bjorklund P. Activating mutations in CTNNB1 in aldosterone
820 producing adenomas. *Sci Rep*.2016; 6:19546
- 821 **30.** Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S,
822 Strom TM, Monticone S, Amar L, Meatchi T, Mantero F, Cicala MV, Quinkler M,
823 Fallo F, Allolio B, Bernini G, Maccario M, Giacchetti G, Jeunemaitre X, Mulatero P,
824 Reincke M, Zennaro MC. Genetic spectrum and clinical correlates of somatic
825 mutations in aldosterone-producing adenoma. *Hypertension*.2014; 64:354-361
- 826 **31.** Daniil G, Fernandes-Rosa FL, Chemin J, Blesneac I, Beltrand J, Polak M, Jeunemaitre
827 X, Boulkroun S, Amar L, Strom TM, Lory P, Zennaro MC. CACNA1H Mutations
828 Are Associated With Different Forms of Primary Aldosteronism. *EBioMedicine*.2016;
829 13:225-236
- 830 **32.** Rhayem Y, Perez-Rivas LG, Dietz A, Bathon K, Gebhard C, Riester A, Mauracher B,
831 Gomez-Sanchez C, Eisenhofer G, Schwarzmayer T, Calebiro D, Strom TM, Reincke
832 M, Beuschlein F. PRKACA Somatic Mutations Are Rare Findings in Aldosterone-
833 Producing Adenomas. *J Clin Endocrinol Metab*.2016; 101:3010-3017
- 834 **33.** Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez-Sanchez CE.
835 Potassium Channel Mutant KCNJ5 T158A Expression in HAC-15 Cells Increases
836 Aldosterone Synthesis. *Endocrinology*.2012; 153:1774-1782
- 837 **34.** Cheng CJ, Sung CC, Wu ST, Lin YC, Sytwu HK, Huang CL, Lin SH. Novel KCNJ5
838 mutations in sporadic aldosterone-producing adenoma reduce Kir3.4 membrane
839 abundance. *J Clin Endocrinol Metab*.2015; 100:E155-163

- 840 **35.** Scholl UI, Nelson-Williams C, Yue P, Grekin R, Wyatt RJ, Dillon MJ, Couch R,
841 Hammer LK, Harley FL, Farhi A, Wang WH, Lifton RP. Hypertension with or
842 without adrenal hyperplasia due to different inherited mutations in the potassium
843 channel KCNJ5. *Proc Natl Acad Sci U S A*.2012; 109:2533-2538
- 844 **36.** Stindl J, Tauber P, Sterner C, Tegtmeier I, Warth R, Bandulik S. Pathogenesis of
845 Adrenal Aldosterone-Producing Adenomas Carrying Mutations of the Na(+)/K(+)-
846 ATPase. *Endocrinology*.2015; 156:4582-4591
- 847 **37.** Tauber P, Aichinger B, Christ C, Stindl J, Rhayem Y, Beuschlein F, Warth R,
848 Bandulik S. Cellular Pathophysiology of an Adrenal Adenoma-Associated Mutant of
849 the Plasma Membrane Ca(2+)-ATPase ATP2B3. *Endocrinology*.2016; 157:2489-2499
- 850 **38.** Catterall WA. Signaling complexes of voltage-gated sodium and calcium channels.
851 *Neurosci Lett*.2010; 486:107-116
- 852 **39.** Dutta RK, Soderkvist P, Gimm O. Genetics of primary hyperaldosteronism. *Endocr*
853 *Relat Cancer*.2016; 23:R437-454
- 854 **40.** Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A,
855 Okada S, Rokutanda N, Takata D, Koibuchi Y, Horiguchi J, Oyama T, Takeyoshi I,
856 Mori M. Expression and Mutations of KCNJ5 mRNA in Japanese Patients with
857 Aldosterone-Producing Adenomas. *J Clin Endocrinol Metab*.2012; 97:1311-1319
- 858 **41.** Kitamoto T, Suematsu S, Matsuzawa Y, Saito J, Omura M, Nishikawa T. Comparison
859 of Cardiovascular Complications in Patients with and without KCNJ5 Gene Mutations
860 Harboring Aldosterone-producing Adenomas. *Journal of atherosclerosis and*
861 *thrombosis*.2014;
- 862 **42.** Zheng FF, Zhu LM, Nie AF, Li XY, Lin JR, Zhang K, Chen J, Zhou WL, Shen ZJ,
863 Zhu YC, Wang JG, Zhu DL, Gao PJ. Clinical characteristics of somatic mutations in

- 864 Chinese patients with aldosterone-producing adenoma. *Hypertension*.2015; 65:622-
865 628
- 866 **43.** Wang B, Li X, Zhang X, Ma X, Chen L, Zhang Y, Lyu X, Tang Y, Huang Q, Gao Y,
867 Fan Y, Ouyang J. Prevalence and characterization of somatic mutations in Chinese
868 aldosterone-producing adenoma patients. *Medicine*.2015; 94:e708
- 869 **44.** Wu VC, Huang KH, Peng KY, Tsai YC, Wu CH, Wang SM, Yang SY, Lin LY,
870 Chang CC, Lin YH, Lin SL, Chu TS, Wu KD. Prevalence and clinical correlates of
871 somatic mutation in aldosterone producing adenoma-Taiwanese population. *Scientific*
872 *reports*.2015; 5:11396
- 873 **45.** Kitamoto T, Suematsu S, Yamazaki Y, Nakamura Y, Sasano H, Matsuzawa Y, Saito J,
874 Omura M, Nishikawa T. Clinical and Steroidogenic Characteristics of Aldosterone-
875 Producing Adenomas With ATPase or CACNA1D Gene Mutations. *J Clin Endocrinol*
876 *Metab*.2016; 101:494-503
- 877 **46.** Hong AR, Kim JH, Song YS, Lee KE, Seo SH, Seong MW, Shin CS, Kim SW, Kim
878 SY. Genetics of Aldosterone-Producing Adenoma in Korean Patients. *PLoS*
879 *One*.2016; 11:e0147590
- 880 **47.** Lenzini L, Rossitto G, Maiolino G, Letizia C, Funder JW, Rossi GP. A Meta-Analysis
881 of Somatic KCNJ5 K(+) Channel Mutations In 1636 Patients With an Aldosterone-
882 Producing Adenoma. *J Clin Endocrinol Metab*.2015; 100:E1089-1095
- 883 **48.** Seccia TM, Mantero F, Letizia C, Kuppusamy M, Caroccia B, Barisa M, Cicala MV,
884 Miotto D, Rossi GP. Somatic mutations in the KCNJ5 gene raise the lateralization
885 index: implications for the diagnosis of primary aldosteronism by adrenal vein
886 sampling. *J Clin Endocrinol Metab*.2012; 97:E2307-2313
- 887 **49.** Osswald A, Fischer E, Degenhart C, Quinkler M, Bidlingmaier M, Pallauf A, Lang K,
888 Mussack T, Hallfeldt K, Beuschlein F, Reincke M. Lack of influence of somatic

- 889 mutations on steroid gradients during adrenal vein sampling in aldosterone-producing
890 adenoma patients. *Eur J Endocrinol.*2013; 169:657-663
- 891 **50.** Akerstrom T, Willenberg HS, Cupisti K, Ip J, Backman S, Moser A, Maharjan R,
892 Robinson B, Iwen KA, Dralle H, C DV, Backdahl M, Botling J, Stalberg P, Westin G,
893 Walz MK, Lehnert H, Sidhu S, Zedenius J, Bjorklund P, Hellman P. Novel somatic
894 mutations and distinct molecular signature in aldosterone-producing adenomas.
895 *Endocr Relat Cancer.*2015; 22:735-744
- 896 **51.** Teo AE, Garg S, Shaikh LH, Zhou J, Karet Frankl FE, Gurnell M, Happerfield L,
897 Marker A, Bienz M, Azizan EA, Brown MJ. Pregnancy, Primary Aldosteronism, and
898 Adrenal CTNNB1 Mutations. *The New England journal of medicine.*2015; 373:1429-
899 1436
- 900 **52.** Murthy M, Xu S, Massimo G, Wolley M, Gordon RD, Stowasser M, O'Shaughnessy
901 KM. Role for germline mutations and a rare coding single nucleotide polymorphism
902 within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary
903 aldosteronism. *Hypertension.*2014; 63:783-789
- 904 **53.** Zilbermint M, Xekouki P, Faucz FR, Berthon A, Gkouroganni A, Schernthaner-Reiter
905 MH, Batsis M, Sinaii N, Quezado MM, Merino M, Hodes A, Abraham SB, Libe R,
906 Assie G, Espiard S, Drougat L, Ragazzon B, Davis A, Gebreab SY, Neff R, Kebebew
907 E, Bertherat J, Lodish MB, Stratakis CA. Primary Aldosteronism and ARMC5
908 Variants. *J Clin Endocrinol Metab.*2015; 100:E900-909
- 909 **54.** Hu C, Rusin CG, Tan Z, Guagliardo NA, Barrett PQ. Zona glomerulosa cells of the
910 mouse adrenal cortex are intrinsic electrical oscillators. *J Clin Invest.*2012; 122:2046-
911 2053
- 912 **55.** Jackson RV, Lafferty A, Torpy DJ, Stratakis C. New genetic insights in familial
913 hyperaldosteronism. *Ann N Y Acad Sci.*2002; 970:77-88

- 914 **56.** Pizzolo F, Trabetti E, Guarini P, Mulatero P, Ciacciarelli A, Blengio GS, Corrocher R,
915 Olivieri O. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive
916 patients from a primary care setting. *J Hum Hypertens.*2005; 19:325-327
- 917 **57.** Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D,
918 Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F. Prevalence and
919 characteristics of familial hyperaldosteronism: the PATOGEN study (Primary
920 Aldosteronism in TOriNO-GENetic forms). *Hypertension.*2011; 58:797-803
- 921 **58.** Aglony M, Martinez-Aguayo A, Carvajal CA, Campino C, Garcia H, Bancalari R,
922 Bolte L, Avalos C, Loureiro C, Trejo P, Brinkmann K, Giadrosich V, Mericq V,
923 Rocha A, Avila A, Perez V, Inostroza A, Fardella CE. Frequency of familial
924 hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and
925 biochemical presentation. *Hypertension.*2011; 57:1117-1121
- 926 **59.** Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in
927 familial and sporadic primary aldosteronism. *Nat Rev Endocrinol.*2013; 9:104-112
- 928 **60.** Scholl UI, Stolting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML,
929 Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG,
930 Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP. Recurrent
931 gain of function mutation in calcium channel CACNA1H causes early-onset
932 hypertension with primary aldosteronism. *Elife.*2015; 4:e06315
- 933 **61.** Adachi M, Muroya K, Asakura Y, Sugiyama K, Homma K, Hasegawa T. Discordant
934 Genotype-Phenotype Correlation in Familial Hyperaldosteronism Type III with
935 KCNJ5 Gene Mutation: A Patient Report and Review of the Literature. *Hormone*
936 *research in paediatrics.*2014; 82:138-142
- 937 **62.** Mulatero P, Tauber P, Zennaro MC, Monticone S, Lang K, Beuschlein F, Fischer E,
938 Tizzani D, Pallauf A, Viola A, Amar L, Williams TA, Strom TM, Graf E, Bandulik S,

- 939 Penton D, Plouin PF, Warth R, Allolio B, Jeunemaitre X, Veglio F, Reincke M.
940 KCNJ5 mutations in European families with nonglucocorticoid remediable familial
941 hyperaldosteronism. *Hypertension*.2012; 59:235-240
- 942 **63.** Boulkroun S, Samson-Couterie B, Dzib JF, Lefebvre H, Louiset E, Amar L, Plouin
943 PF, Lalli E, Jeunemaitre X, Benecke A, Meatchi T, Zennaro MC. Adrenal cortex
944 remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism.
945 *Hypertension*.2010; 56:885-892
- 946 **64.** Neville AM, O'Hare MJ. Histopathology of the human adrenal cortex. *Clin Endocrinol*
947 *Metab*.1985; 14:791-820
- 948 **65.** Gomez-Sanchez CE. Channels and pumps in aldosterone-producing adenomas. *J Clin*
949 *Endocrinol Metab*.2014; 99:1152-1156
- 950 **66.** Dekkers T, ter Meer M, Lenders JW, Hermus AR, Schultze Kool L, Langenhuijsen JF,
951 Nishimoto K, Ogishima T, Mukai K, Azizan EA, Tops B, Deinum J, Kusters B.
952 Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the
953 culprit? *J Clin Endocrinol Metab*.2014; 99:E1341-1351
- 954 **67.** Fernandes-Rosa FL, Giscos-Douriez I, Amar L, Gomez-Sanchez CE, Meatchi T,
955 Boulkroun S, Zennaro MC. Different Somatic Mutations in Multinodular Adrenals
956 With Aldosterone-Producing Adenoma. *Hypertension*.2015; 66:1014-1022
- 957 **68.** Nanba K, Chen AX, Omata K, Vinco M, Giordano TJ, Else T, Hammer GD, Tomlins
958 SA, Rainey WE. Molecular Heterogeneity in Aldosterone-Producing Adenomas. *J*
959 *Clin Endocrinol Metab*.2016; 101:999-1007
- 960 **69.** Vouillarmet J, Fernandes-Rosa F, Graeppi-Dulac J, Lantelme P, Decaussin-Petrucci
961 M, Thivolet C, Peix JL, Boulkroun S, Clauser E, Zennaro MC. Aldosterone-Producing
962 Adenoma With a Somatic KCNJ5 Mutation Revealing APC-Dependent Familial
963 Adenomatous Polyposis. *J Clin Endocrinol Metab*.2016; 101:3874-3878

- 964 **70.** Nishimoto K, Nakagawa K, Li D, Kosaka T, Oya M, Mikami S, Shibata H, Itoh H,
965 Mitani F, Yamazaki T, Ogishima T, Suematsu M, Mukai K. Adrenocortical zonation
966 in humans under normal and pathological conditions. *J Clin Endocrinol Metab.*2010;
967 95:2296-2305
- 968 **71.** Boulkroun S, Samson-Couterie B, Golib-Dzib JF, Amar L, Plouin PF, Sibony M,
969 Lefebvre H, Louiset E, Jeunemaitre X, Meatchi T, Benecke A, Lalli E, Zennaro MC.
970 Aldosterone-producing adenoma formation in the adrenal cortex involves expression
971 of stem/progenitor cell markers. *Endocrinology.*2011; 152:4753-4763
- 972 **72.** Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ,
973 Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE.
974 Aldosterone-stimulating somatic gene mutations are common in normal adrenal
975 glands. *Proc Natl Acad Sci U S A.*2015; 112:E4591-4599
- 976 **73.** Yamazaki Y, Nakamura Y, Omata K, Ise K, Tezuka Y, Ono Y, Morimoto R, Nozawa
977 Y, Gomez-Sanchez CE, Tomlins SA, Rainey WE, Ito S, Satoh F, Sasano H.
978 Histopathological classification of cross-sectional image negative hyperaldosteronism.
979 *The Journal of clinical endocrinology and metabolism.*2016:jc20162986
- 980 **74.** Nishimoto K, Seki T, Kurihara I, Yokota K, Omura M, Nishikawa T, Shibata H,
981 Kosaka T, Oya M, Suematsu M, Mukai K. Case Report: Nodule Development From
982 Subcapsular Aldosterone-Producing Cell Clusters Causes Hyperaldosteronism. *J Clin*
983 *Endocrinol Metab.*2016; 101:6-9
- 984 **75.** Beuschlein F, Fassnacht M, Assie G, Calebiro D, Stratakis CA, Osswald A, Ronchi
985 CL, Wieland T, Sbiera S, Faucz FR, Schaak K, Schmittfull A, Schwarzmayr T,
986 Barreau O, Vezzosi D, Rizk-Rabin M, Zabel U, Szarek E, Salpea P, Forlino A, Vetro
987 A, Zuffardi O, Kisker C, Diener S, Meitinger T, Lohse MJ, Reincke M, Bertherat J,

988 Strom TM, Allolio B. Constitutive activation of PKA catalytic subunit in adrenal
989 Cushing's syndrome. *The New England journal of medicine*.2014; 370:1019-1028

990 **76.** Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, Kunstman JW,
991 Korah R, Suttorp AC, Dietrich D, Haase M, Willenberg HS, Stalberg P, Hellman P,
992 Akerstrom G, Bjorklund P, Carling T, Lifton RP. Recurrent activating mutation in
993 PRKACA in cortisol-producing adrenal tumors. *Nat Genet*.2014; 46:613-617

994 **77.** Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, Zhou W, Li X, Zhong X, Lei Y, Su T,
995 Wang H, Jiang Y, Yang L, Wei W, Yang X, Jiang X, Liu L, He J, Ye J, Wei Q, Li Y,
996 Wang W, Wang J, Ning G. Activating hotspot L205R mutation in PRKACA and
997 adrenal Cushing's syndrome. *Science*.2014; 344:913-917

998 **78.** Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, Shiraishi Y, Yoshida K, Nagata
999 Y, Sato-Otsubo A, Yoshizato T, Suzuki H, Shiozawa Y, Kataoka K, Kon A, Aoki K,
1000 Chiba K, Tanaka H, Kume H, Miyano S, Fukayama M, Nureki O, Homma Y, Ogawa
1001 S. Recurrent somatic mutations underlie corticotropin-independent Cushing's
1002 syndrome. *Science*.2014; 344:917-920

1003 **79.** Thiel A, Reis AC, Haase M, Goh G, Schott M, Willenberg HS, Scholl UI. PRKACA
1004 mutations in cortisol-producing adenomas and adrenal hyperplasia: a single-center
1005 study of 60 cases. *Eur J Endocrinol*.2015; 172:677-685

1006 **80.** Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, Shibusawa N, Ozawa A,
1007 Ishii S, Tomaru T, Horiguchi K, Okada S, Takata D, Rokutanda N, Horiguchi J,
1008 Tsushima Y, Oyama T, Takeyoshi I, Yamada M. Somatic mutations of the catalytic
1009 subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients
1010 with several adrenal adenomas secreting cortisol [Rapid Communication]. *Endocr*
1011 *J*.2014; 61:825-832

- 1012 **81.** Nakajima Y, Okamura T, Horiguchi K, Gohko T, Miyamoto T, Satoh T, Ozawa A,
1013 Ishii S, Yamada E, Hashimoto K, Okada S, Takata D, Horiguchi J, Yamada M. GNAS
1014 mutations in adrenal aldosterone-producing adenomas. *Endocr J.*2016; 63:199-204
- 1015 **82.** Ronchi CL, Di Dalmazi G, Faillot S, Sbiera S, Assie G, Weigand I, Calebiro D,
1016 Schwarzmayer T, Appenzeller S, Rubin B, Waldmann J, Scaroni C, Bartsch DK,
1017 Mantero F, Mannelli M, Kastelan D, Chiodini I, Bertherat J, Reincke M, Strom TM,
1018 Fassnacht M, Beuschlein F, European Network for the Study of Adrenocortical T.
1019 Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without
1020 PRKACA p.Leu206Arg Mutation. *J Clin Endocrinol Metab.*2016; 101:3526-3538
- 1021 **83.** Nakajima Y, Yamada M, Taguchi R, Satoh T, Hashimoto K, Ozawa A, Shibusawa N,
1022 Okada S, Monden T, Mori M. Cardiovascular complications of patients with
1023 aldosteronism associated with autonomous cortisol secretion. *J Clin Endocrinol*
1024 *Metab.*2011; 96:2512-2518
- 1025 **84.** Gomez-Sanchez CE, Gomez-Sanchez EP. Immunohistochemistry of the adrenal in
1026 primary aldosteronism. *Curr Opin Endocrinol Diabetes Obes.*2016; 23:242-248
- 1027 **85.** Yamada M, Nakajima Y, Taguchi R, Okamura T, Ishii S, Tomaru T, Ozawa A,
1028 Shibusawa N, Yoshino S, Toki A, Ishida E, Hashimoto K, Satoh T, Mori M. KCNJ5
1029 mutations in aldosterone- and cortisol-co-secreting adrenal adenomas. *Endocr J.*2012;
1030 59:735-741
- 1031 **86.** Fallo F, Bertello C, Tizzani D, Fassina A, Boulkroun S, Sonino N, Monticone S, Viola
1032 A, Veglio F, Mulatero P. Concurrent primary aldosteronism and subclinical cortisol
1033 hypersecretion: a prospective study. *J Hypertens.*2011; 29:1773-1777
- 1034 **87.** Nanba K, Omata K, Tomlins SA, Giordano TJ, Hammer GD, Rainey WE, Else T.
1035 Double adrenocortical adenomas harboring independent KCNJ5 and PRKACA
1036 somatic mutations. *Eur J Endocrinol.*2016; 175:K1-6

- 1037 **88.** Heikkila M, Peltoketo H, Leppaluoto J, Ilves M, Vuolteenaho O, Vainio S. Wnt-4
1038 deficiency alters mouse adrenal cortex function, reducing aldosterone production.
1039 *Endocrinology*.2002; 143:4358-4365
- 1040 **89.** Mandel H, Shemer R, Borochowitz ZU, Okopnik M, Knopf C, Indelman M, Drugan
1041 A, Tiosano D, Gershoni-Baruch R, Choder M, Sprecher E. SERKAL syndrome: an
1042 autosomal-recessive disorder caused by a loss-of-function mutation in WNT4.
1043 *American journal of human genetics*.2008; 82:39-47
- 1044 **90.** Bingham NC, Verma-Kurvari S, Parada LF, Parker KL. Development of a
1045 steroidogenic factor 1/Cre transgenic mouse line. *Genesis*.2006; 44:419-424
- 1046 **91.** Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, Lavery GG, Parker
1047 KL, Hammer GD. Targeted disruption of beta-catenin in Sf1-expressing cells impairs
1048 development and maintenance of the adrenal cortex. *Development*.2008; 135:2593-
1049 2602
- 1050 **92.** Salomon A, Keramidas M, Maisin C, Thomas M. Loss of beta-catenin in
1051 adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-
1052 mesenchymal transition. *Oncotarget*.2015; 6:11421-11433
- 1053 **93.** Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple
1054 intestinal neoplasia in the mouse. *Science*.1990; 247:322-324
- 1055 **94.** Bhandaru M, Kempe DS, Rotte A, Rexhepaj R, Kuhl D, Lang F. Hyperaldosteronism,
1056 hypervolemia, and increased blood pressure in mice expressing defective APC. *Am J*
1057 *Physiol Regul Integr Comp Physiol*.2009; 297:R571-575
- 1058 **95.** Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-
1059 Soubeyrand C, Louiset E, Taketo MM, Tissier F, Bertherat J, Lefrancois-Martinez
1060 AM, Martinez A, Val P. Constitutive beta-catenin activation induces adrenal

1061 hyperplasia and promotes adrenal cancer development. *Hum Mol Genet.*2010;
1062 19:1561-1576

1063 **96.** Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagnere AM, Rene-Corail
1064 F, Jullian E, Gicquel C, Bertagna X, Vacher-Lavenu MC, Perret C, Bertherat J.
1065 Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling
1066 pathway is a frequent event in both benign and malignant adrenocortical tumors.
1067 *Cancer Res.*2005; 65:7622-7627

1068 **97.** Bonnet S, Gaujoux S, Launay P, Baudry C, Chokri I, Ragazzon B, Libe R, Rene-
1069 Corail F, Audebourg A, Vacher-Lavenu MC, Groussin L, Bertagna X, Dousset B,
1070 Bertherat J, Tissier F. Wnt/beta-catenin pathway activation in adrenocortical
1071 adenomas is frequently due to somatic CTNNB1-activating mutations, which are
1072 associated with larger and nonsecreting tumors: a study in cortisol-secreting and -
1073 nonsecreting tumors. *J Clin Endocrinol Metab.*2011; 96:E419-426

1074 **98.** Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, Samson-Couterie
1075 B, Zennaro MC, Plouin PF, Skah S, Plateroti M, Lefebvre H, Sahut-Barnola I, Batisse-
1076 Lignier M, Assie G, Lefrancois-Martinez AM, Bertherat J, Martinez A, Val P.
1077 WNT/beta-catenin signalling is activated in aldosterone-producing adenomas and
1078 controls aldosterone production. *Hum Mol Genet.*2014; 23:889-905

1079 **99.** Wu VC, Wang SM, Chueh SJ, Yang SY, Huang KH, Lin YH, Wang JJ, Connolly R,
1080 Hu YH, Gomez-Sanchez CE, Peng KY, Wu KD. The prevalence of CTNNB1
1081 mutations in primary aldosteronism and consequences for clinical outcomes. *Scientific*
1082 *reports.*2017; 7:39121

1083 **100.** Berthon A, Drelon C, Val P. Pregnancy, Primary Aldosteronism, and Somatic
1084 CTNNB1 Mutations. *The New England journal of medicine.*2016; 374:1493-1494

- 1085 **101.** Murtha TD, Carling T, Scholl UI. Pregnancy, Primary Aldosteronism, and Somatic
1086 CTNNB1 Mutations. *N Engl J Med.*2016; 374:1492-1493
- 1087 **102.** Drelon C, Berthon A, Sahut-Barnola I, Mathieu M, Dumontet T, Rodriguez S, Batisse-
1088 Lignier M, Tabbal H, Tauveron I, Lefrancois-Martinez AM, Pointud JC, Gomez-
1089 Sanchez CE, Vainio S, Shan J, Sacco S, Schedl A, Stratakis CA, Martinez A, Val P.
1090 PKA inhibits WNT signalling in adrenal cortex zonation and prevents malignant
1091 tumour development. *Nature communications.*2016; 7:12751
- 1092 **103.** De Venanzi A, Alencar GA, Bourdeau I, Fragoso MC, Lacroix A. Primary bilateral
1093 macronodular adrenal hyperplasia. *Curr Opin Endocrinol Diabetes Obes.*2014;
1094 21:177-184
- 1095 **104.** Lefebvre H, Prevost G, Louiset E. Autocrine/paracrine regulatory mechanisms in
1096 adrenocortical neoplasms responsible for primary adrenal hypercorticism. *European*
1097 *journal of endocrinology.*2013; 169:R115-138
- 1098 **105.** Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, Hamet
1099 P, Bourdeau I, Zerbini MC, Pereira MA, Gomes GC, Rocha Mde S, Chambo JL,
1100 Lacroix A, Mendonca BB, Fragoso MC. ARMC5 mutations are a frequent cause of
1101 primary macronodular adrenal Hyperplasia. *The Journal of clinical endocrinology and*
1102 *metabolism.*2014; 99:E1501-1509
- 1103 **106.** Fragoso MC, Alencar GA, Lerario AM, Bourdeau I, Almeida MQ, Mendonca BB,
1104 Lacroix A. Genetics of primary macronodular adrenal hyperplasia. *J Endocrinol.*2015;
1105 224:R31-43
- 1106 **107.** Lacroix A. ACTH-independent macronodular adrenal hyperplasia. *Best Pract Res Clin*
1107 *Endocrinol Metab.*2009; 23:245-259

- 1108 **108.** Drougat L, Espiard S, Bertherat J. Genetics of primary bilateral macronodular adrenal
1109 hyperplasia: a model for early diagnosis of Cushing's syndrome? *Eur J*
1110 *Endocrinol.*2015; 173:M121-131
- 1111 **109.** Yamada Y, Sakaguchi K, Inoue T, Kubo M, Fushimi H, Sekii K, Itatani H, Tsujimura
1112 T, Kameyama M. Preclinical Cushing's syndrome due to adrenocorticotropin-
1113 independent bilateral adrenocortical macronodular hyperplasia with concurrent excess
1114 of gluco- and mineralocorticoids. *Intern Med.*1997; 36:628-632
- 1115 **110.** Hayashi Y, Takeda Y, Kaneko K, Koyama H, Aiba M, Ikeda U, Shimada K. A case of
1116 Cushing's syndrome due to ACTH-independent bilateral macronodular hyperplasia
1117 associated with excessive secretion of mineralocorticoids. *Endocr J.*1998; 45:485-491
- 1118 **111.** Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors
1119 in adrenal Cushing's syndrome. *Endocrine reviews.*2001; 22:75-110
- 1120 **112.** Bourdeau I, D'Amour P, Hamet P, Boutin JM, Lacroix A. Aberrant membrane
1121 hormone receptors in incidentally discovered bilateral macronodular adrenal
1122 hyperplasia with subclinical Cushing's syndrome. *J Clin Endocrinol Metab.*2001;
1123 86:5534-5540
- 1124 **113.** Assie G, Libe R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefevre
1125 L, Sibony M, Guignat L, Rodriguez S, Perlemoine K, Rene-Corail F, Letourneur F,
1126 Trabulsi B, Poussier A, Chabbert-Buffet N, Borson-Chazot F, Groussin L, Bertagna
1127 X, Stratakis CA, Ragazzon B, Bertherat J. ARMC5 mutations in macronodular adrenal
1128 hyperplasia with Cushing's syndrome. *N Engl J Med.*2013; 369:2105-2114
- 1129 **114.** Correa R, Zilbermint M, Berthon A, Espiard S, Batsis M, Papadakis GZ, Xekouki P,
1130 Lodish MB, Bertherat J, Faucz FR, Stratakis CA. The ARMC5 gene shows extensive
1131 genetic variance in primary macronodular adrenocortical hyperplasia. *European*
1132 *journal of endocrinology.*2015; 173:435-440

- 1133 **115.** Drougat L, Omeiri H, Lefevre L, Ragazzon B. Novel Insights into the Genetics and
1134 Pathophysiology of Adrenocortical Tumors. *Frontiers in endocrinology*.2015; 6:96
- 1135 **116.** Berthon A, Faucz F, Bertherat J, Stratakis CA. Analysis of ARMC5 expression in
1136 human tissues. *Molecular and cellular endocrinology*.2017; 441:140-145
- 1137 **117.** Hu Y, Lao L, Mao J, Jin W, Luo H, Charpentier T, Qi S, Peng J, Hu B, Marcinkiewicz
1138 MM, Lamarre A, Wu J. Armc5 deletion causes developmental defects and
1139 compromises T-cell immune responses. *Nature communications*.2017; 8:13834
- 1140 **118.** Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, Berthon A, Libe
1141 R, Assie G, Espiard S, Drougat L, Ragazzon B, Bertherat J, Stratakis CA.
1142 Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing
1143 5 (ARMC5) gene: a clinical and genetic investigation. *J Clin Endocrinol Metab*.2014;
1144 99:E1113-1119
- 1145 **119.** Espiard S, Drougat L, Libe R, Assie G, Perlemoine K, Guignat L, Barrande G,
1146 Brucker-Davis F, Doullay F, Lopez S, Sonnet E, Torremocha F, Pinsard D, Chabbert-
1147 Buffet N, Raffin-Sanson ML, Groussin L, Borson-Chazot F, Coste J, Bertagna X,
1148 Stratakis CA, Beuschlein F, Ragazzon B, Bertherat J. ARMC5 Mutations in a Large
1149 Cohort of Primary Macronodular Adrenal Hyperplasia: Clinical and Functional
1150 Consequences. *The Journal of clinical endocrinology and metabolism*.2015;
1151 100:E926-935
- 1152 **120.** Albiger NM, Regazzo D, Rubin B, Ferrara AM, Rizzati S, Taschin E, Ceccato F,
1153 Arnaldi G, Pecori Giraldi F, Stigliano A, Cerquetti L, Grimaldi F, De Menis E,
1154 Boscaro M, Iacobone M, Occhi G, Scaroni C. A multicenter experience on the
1155 prevalence of ARMC5 mutations in patients with primary bilateral macronodular
1156 adrenal hyperplasia: from genetic characterization to clinical phenotype.
1157 *Endocrine*.2017; 55:959-968

- 1158 **121.** Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, Hotu C, Oftedal
1159 BE, Cutfield R, Adelson DL, Braund WJ, Gordon RD, Rees DA, Grossman AB,
1160 Torpy DJ, Scott HS. ARMC5 mutations are common in familial bilateral
1161 macronodular adrenal hyperplasia. *The Journal of clinical endocrinology and*
1162 *metabolism*.2014; 99:E1784-1792
- 1163 **122.** Elbelt U, Trovato A, Kloth M, Gentz E, Finke R, Spranger J, Galas D, Weber S, Wolf
1164 C, Konig K, Arlt W, Buttner R, May P, Allolio B, Schneider JG. Molecular and
1165 clinical evidence for an ARMC5 tumor syndrome: concurrent inactivating germline
1166 and somatic mutations are associated with both primary macronodular adrenal
1167 hyperplasia and meningioma. *The Journal of clinical endocrinology and*
1168 *metabolism*.2015; 100:E119-128
- 1169 **123.** Bourdeau I, Oble S, Magne F, Levesque I, Caceres-Gorriti KY, Nolet S, Awadalla P,
1170 Tremblay J, Hamet P, Fragoso MC, Lacroix A. ARMC5 mutations in a large French-
1171 Canadian family with cortisol-secreting beta-adrenergic/vasopressin responsive
1172 bilateral macronodular adrenal hyperplasia. *European journal of endocrinology*.2016;
1173 174:85-96
- 1174 **124.** Zilbermint M, Xekouki P, Faucz FR, Berthon A, Gkouroganni A, Helene
1175 Schernthaner-Reiter M, Batsis M, Sinaii N, Quezado MM, Merino M, Hodes A,
1176 Abraham SB, Libe R, Assie G, Espiard S, Drougat L, Ragazzon B, Davis A, Gebreab
1177 SY, Neff R, Kebebew E, Bertherat J, Lodish MB, Stratakis CA. Primary
1178 Aldosteronism and ARMC5 variants. *J Clin Endocrinol Metab*.2015;jc20144167
- 1179 **125.** Mulatero P, Schiavi F, Williams TA, Monticone S, Barbon G, Opocher G, Fallo F.
1180 ARMC5 mutation analysis in patients with primary aldosteronism and bilateral
1181 adrenal lesions. *J Hum Hypertens*.2016; 30:374-378

- 1182 **126.** Leoz ML, Carballal S, Moreira L, Ocana T, Balaguer F. The genetic basis of familial
1183 adenomatous polyposis and its implications for clinical practice and risk management.
1184 *Appl Clin Genet.*2015; 8:95-107
- 1185 **127.** Smith TG, Clark SK, Katz DE, Reznik RH, Phillips RK. Adrenal masses are
1186 associated with familial adenomatous polyposis. *Diseases of the colon and*
1187 *rectum.*2000; 43:1739-1742
- 1188 **128.** Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P,
1189 Meatchi T, Libe R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J.
1190 Inactivation of the APC gene is constant in adrenocortical tumors from patients with
1191 familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers.
1192 *Clin Cancer Res.*2010; 16:5133-5141
- 1193 **129.** Hsiao HP, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White
1194 AJ, Nesterova M, Lacroix A, Stratakis CA. Clinical and genetic heterogeneity, overlap
1195 with other tumor syndromes, and atypical glucocorticoid hormone secretion in
1196 adrenocorticotropin-independent macronodular adrenal hyperplasia compared with
1197 other adrenocortical tumors. *J Clin Endocrinol Metab.*2009; 94:2930-2937
- 1198 **130.** Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple
1199 endocrine neoplasia type 1: clinical and genetic topics. *Ann Intern Med.*1998;
1200 129:484-494
- 1201 **131.** Balogh K, Racz K, Patocs A, Hunyady L. Menin and its interacting proteins:
1202 elucidation of menin function. *Trends in endocrinology and metabolism: TEM.*2006;
1203 17:357-364
- 1204 **132.** Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, Young
1205 J, Delemer B, Du Boullay H, Verger MF, Kuhn JM, Sadoul JL, Ruzniewski P,
1206 Beckers A, Monsaingeon M, Baudin E, Goudet P, Tabarin A. Adrenal involvement in

1207 MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines
1208 database. *Eur J Endocrinol.*2012; 166:269-279

1209 **133.** Iida A, Blake K, Tunny T, Klemm S, Stowasser M, Hayward N, Gordon R, Nakamura
1210 Y, Imai T. Allelic losses on chromosome band 11q13 in aldosterone-producing
1211 adrenal tumors. *Genes Chromosomes Cancer.*1995; 12:73-75.

1212 **134.** Matyakhina L, Freedman RJ, Bourdeau I, Wei MH, Stergiopoulos SG, Chidakel A,
1213 Walther M, Abu-Asab M, Tsokos M, Keil M, Toro J, Linehan WM, Stratakis CA.
1214 Hereditary leiomyomatosis associated with bilateral, massive, macronodular
1215 adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic
1216 investigation. *J Clin Endocrinol Metab.*2005; 90:3773-3779

1217 **135.** Shuch B, Ricketts CJ, Vocke CD, Valera VA, Chen CC, Gautam R, Gupta GN,
1218 Gomez Macias GS, Merino MJ, Bratslavsky G, Linehan WM. Adrenal nodular
1219 hyperplasia in hereditary leiomyomatosis and renal cell cancer. *J Urol.*2013; 189:430-
1220 435

1221 **136.** Brown RJ, Kelly MH, Collins MT. Cushing syndrome in the McCune-Albright
1222 syndrome. *The Journal of clinical endocrinology and metabolism.*2010; 95:1508-1515

1223 **137.** Fragoso MC, Domenice S, Latronico AC, Martin RM, Pereira MA, Zerbini MC,
1224 Lucon AM, Mendonca BB. Cushing's syndrome secondary to adrenocorticotropin-
1225 independent macronodular adrenocortical hyperplasia due to activating mutations of
1226 GNAS1 gene. *J Clin Endocrinol Metab.*2003; 88:2147-2151

1227 **138.** Libe R, Fratticci A, Coste J, Tissier F, Horvath A, Ragazzon B, Rene-Corail F,
1228 Groussin L, Bertagna X, Raffin-Sanson ML, Stratakis CA, Bertherat J.
1229 Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical
1230 tumors. *Clinical cancer research : an official journal of the American Association for*
1231 *Cancer Research.*2008; 14:4016-4024

- 1232 **139.** Vezzosi D, Libe R, Baudry C, Rizk-Rabin M, Horvath A, Levy I, Rene-Corail F,
1233 Ragazzon B, Stratakis CA, Vandecasteele G, Bertherat J. Phosphodiesterase 11A
1234 (PDE11A) gene defects in patients with acth-independent macronodular adrenal
1235 hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of
1236 bilateral adrenal tumors. *The Journal of clinical endocrinology and metabolism*.2012;
1237 97:E2063-2069
- 1238 **140.** Swords FM, Baig A, Malchoff DM, Malchoff CD, Thorner MO, King PJ, Hunyady L,
1239 Clark AJ. Impaired desensitization of a mutant adrenocorticotropin receptor associated
1240 with apparent constitutive activity. *Mol Endocrinol*.2002; 16:2746-2753
- 1241 **141.** Carney JA, Lyssikatos C, Lodish MB, Stratakis CA. Germline PRKACA
1242 amplification leads to Cushing syndrome caused by 3 adrenocortical pathologic
1243 phenotypes. *Human pathology*.2015; 46:40-49
- 1244 **142.** Tauber P, Penton D, Stindl J, Humberg E, Tegtmeier I, Sterner C, Beuschlein F,
1245 Reincke M, Barhanin J, Bandulik S, Warth R. Pharmacology and pathophysiology of
1246 mutated KCNJ5 found in adrenal aldosterone producing adenomas.
1247 *Endocrinology*.2014:en20131944
- 1248 **143.** Scholl UI, Abriola L, Zhang C, Reimer EN, Plummer M, Kazmierczak BI, Zhang J,
1249 Hoyer D, Merkel JS, Wang W, Lifton RP. Macrolides selectively inhibit mutant
1250 KCNJ5 potassium channels that cause aldosterone-producing adenoma. *J Clin*
1251 *Invest*.2017; 127:2739-2750
- 1252 **144.** Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, Feuchtinger A, Chortis V,
1253 Gilligan LC, Ludwig P, Riester A, Asbach E, Hughes BA, O'Neil DM, Bidlingmaier
1254 M, Tomlinson JW, Hassan-Smith ZK, Rees DA, Adolf C, Hahner S, Quinkler M,
1255 Dekkers T, Deinum J, Biehl M, Keevil BG, Shackleton CHL, Deeks JJ, Walch AK,

1256 Beuschlein F, Reincke M. Steroid metabolome analysis reveals prevalent
1257 glucocorticoid excess in primary aldosteronism. *JCI Insight*.2017; 2

1258 **145.** Boulkroun S, Beuschlein F, Rossi GP, Golib-Dzib JF, Fischer E, Amar L, Mulatero P,
1259 Samson-Couterie B, Hahner S, Quinkler M, Fallo F, Letizia C, Allolio B, Ceolotto G,
1260 Cicala MV, Lang K, Lefebvre H, Lenzini L, Maniero C, Monticone S, Perrocheau M,
1261 Pilon C, Plouin PF, Rayes N, Seccia TM, Veglio F, Williams TA, Zinamosca L,
1262 Mantero F, Benecke A, Jeunemaitre X, Reincke M, Zennaro MC. Prevalence, Clinical,
1263 and Molecular Correlates of KCNJ5 Mutations in Primary Aldosteronism.
1264 *Hypertension*.2012; 59:592-598

1265 **146.** Boulkroun S, Golib Dzib JF, Samson-Couterie B, Rosa FL, Rickard AJ, Meatchi T,
1266 Amar L, Benecke A, Zennaro MC. KCNJ5 mutations in aldosterone producing
1267 adenoma and relationship with adrenal cortex remodeling. *Mol Cell Endocrinol*.2013;
1268 371:221-227

1269 **147.** Akerstrom T, Crona J, Delgado Verdugo A, Starker LF, Cupisti K, Willenberg HS,
1270 Knoefel WT, Saeger W, Feller A, Ip J, Soon P, Anlauf M, Alesina PF, Schmid KW,
1271 Decaussin M, Levillain P, Wangberg B, Peix JL, Robinson B, Zedenius J, Backdahl
1272 M, Caramuta S, Iwen KA, Botling J, Stalberg P, Kraimps JL, Dralle H, Hellman P,
1273 Sidhu S, Westin G, Lehnert H, Walz MK, Akerstrom G, Carling T, Choi M, Lifton
1274 RP, Bjorklund P. Comprehensive re-sequencing of adrenal aldosterone producing
1275 lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity
1276 filter. *PLoS One*.2012; 7:e41926

1277 **148.** Azizan EA, Murthy M, Stowasser M, Gordon R, Kowalski B, Xu S, Brown MJ,
1278 O'Shaughnessy KM. Somatic Mutations Affecting the Selectivity Filter of KCNJ5 Are
1279 Frequent in 2 Large Unselected Collections of Adrenal Aldosteronomas.
1280 *Hypertension*.2012; 59:587-591

- 1281 **149.** Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker
1282 A, Hoffman GJ, Brown MJ. Microarray, qPCR, and KCNJ5 Sequencing of
1283 Aldosterone-Producing Adenomas Reveal Differences in Genotype and Phenotype
1284 between Zona Glomerulosa- and Zona Fasciculata-Like Tumors. *J Clin Endocrinol*
1285 *Metab.*2012; 97:E819-829
- 1286 **150.** Williams TA, Monticone S, Schack VR, Stindl J, Burrello J, Buffolo F, Annaratone L,
1287 Castellano I, Beuschlein F, Reincke M, Lucatello B, Ronconi V, Fallo F, Bernini G,
1288 Maccario M, Giacchetti G, Veglio F, Warth R, Vilsen B, Mulatero P. Somatic
1289 ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas.
1290 *Hypertension.*2014; 63:188-195
- 1291 **151.** Kuppusamy M, Caroccia B, Stindl J, Bandulik S, Lenzini L, Gioco F, Fishman V,
1292 Zanotti G, Gomez-Sanchez C, Bader M, Warth R, Rossi GP. A novel KCNJ5-insT149
1293 somatic mutation close to, but outside, the selectivity filter causes resistant
1294 hypertension by loss of selectivity for potassium. *J Clin Endocrinol Metab.*2014;
1295 99:E1765-1773
- 1296 **152.** Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE,
1297 Williams TA, Mulatero P. Immunohistochemical, genetic and clinical characterization
1298 of sporadic aldosterone-producing adenomas. *Mol Cell Endocrinol.*2015; 411:146-154
- 1299 **153.** Murthy M, Azizan EA, Brown MJ, O'Shaughnessy KM. Characterization of a novel
1300 somatic KCNJ5 mutation delI157 in an aldosterone-producing adenoma. *Journal of*
1301 *hypertension.*2012; 30:1827-1833
- 1302 **154.** Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA,
1303 Sterner C, Warth R, Mulatero P, Rainey WE. a Novel Y152C KCNJ5 mutation
1304 responsible for familial hyperaldosteronism type III. *J Clin Endocrinol Metab.*2013;
1305 98:E1861-1865

- 1306 **155.** Hardege I, Xu S, Gordon RD, Thompson AJ, Figg N, Stowasser M, Murrell-Lagnado
1307 R, O'Shaughnessy KM. Novel Insertion Mutation in KCNJ5 Channel Produces
1308 Constitutive Aldosterone Release From H295R Cells. *Molecular endocrinology*.2015;
1309 29:1522-1530
- 1310 **156.** Dutta RK, Welander J, Brauckhoff M, Walz M, Alesina P, Arnesen T, Soderkvist P,
1311 Gimm O. Complementary somatic mutations of KCNJ5, ATP1A1, and ATP2B3 in
1312 sporadic aldosterone producing adrenal adenomas. *Endocrine-related cancer*.2014;
1313 21:L1-4
- 1314 **157.** Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, Quinkler M,
1315 Rayes N, Tabarin A, Laure Jullie M, Mantero F, Rubin B, Waldmann J, Bartsch DK,
1316 Pasquali R, Lohse M, Allolio B, Fassnacht M, Beuschlein F, Reincke M. Novel
1317 somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal
1318 Cushing's syndrome: a European multicentric study. *J Clin Endocrinol Metab*.2014;
1319 99:E2093-2100
- 1320 **158.** Okamura T, Nakajima Y, Katano-Toki A, Horiguchi K, Matsumoto S, Yoshino S,
1321 Yamada E, Tomaru T, Ishii S, Saito T, Ozawa A, Shibusawa N, Satoh T, Okada S,
1322 Nagaoka R, Takada D, Horiguchi J, Oyama T, Yamada M. Characteristics of Japanese
1323 aldosterone-producing adenomas with KCNJ5 mutations. *Endocr J*.2017; 64:39-47
1324
1325

1326 **Figure legends**

1327

1328 **Figure 1. Specific and common mechanism of aldosterone and cortisol producing**

1329 **adenoma development. A. Specific mechanisms of APA formation.** In absence of

1330 stimulation (AngII or K^+), ZG cells are hyperpolarized due to the presence of a large number

1331 of K^+ channels. In response to an increase of extracellular K^+ concentration or to the binding

1332 of AngII to its receptor (AT1R), inhibition of K^+ channels leads to cell membrane

1333 depolarization, opening of voltage gated Ca^{2+} channels, increased intracellular calcium

1334 concentrations and activation of Ca^{2+} signaling, the major trigger for aldosterone biosynthesis.

1335 Moreover, binding of AngII to AT1R leads to the inhibition of the Na^+/K^+ -ATPase, increasing

1336 cell depolarization, whereas signaling through $G\alpha_q$ promotes the release of Ca^{2+} from the

1337 endoplasmatic reticulum through binding of IP3 to its receptor, again stimulating aldosterone

1338 biosynthesis. Mutations in *KCNJ5*, encoding the GIRK4 potassium channel, induce changes

1339 in channel selectivity, allowing Na^+ entry into the cell instead of K^+ efflux, resulting in cell

1340 depolarization, opening of voltage gated Ca^{2+} channel, stimulation of Ca^{2+} signaling and

1341 increase in aldosterone production. Mutations in *ATP1A1*, coding for the $\alpha 1$ subunit of the

1342 Na^+/K^+ -ATPase, lead to increased aldosterone production by increasing intracellular Na^+ and

1343 H^+ concentration, resulting in cell membrane depolarization and decrease of intracellular pH.

1344 Mutations in *CACNA1D*, encoding the Cav1.3 calcium channel, and *ATP2B3*, coding for the

1345 Ca^{2+} pump PMCA3 directly affect intracellular Ca^{2+} concentrations and thus aldosterone

1346 biosynthesis. **B. Specific mechanisms of CPA formation.** In absence of stimulation, the

1347 catalytic and regulatory subunits of the PKA form an inactive complex. Binding of ACTH to

1348 its receptor, the melanocortin 2 receptor (MC2R), leads to activation of adenylate cyclase

1349 resulting in an increase of cAMP. cAMP binds to the regulatory subunits of the PKA

1350 complex, inducing conformational changes and release of the catalytic subunits from the

1351 complex. Active PKA phosphorylates specific target proteins such as the transcription factor

1352 CREB that binds to the promoter regions of specific target genes, ie CYP11B1 leading to
1353 increased cortisol biosynthesis. In cells, the cAMP is converted into AMP through the action
1354 of specific PDE. Mutations in *PRKACA* or in *GNAS* lead to the constitutive activation of
1355 PKA, phosphorylation of CREB and increased expression of CYP11B1 and autonomous
1356 cortisol biosynthesis. **C. Common mechanisms of APA and CPA formation.** In
1357 unstimulated cells, β -catenin is phosphorylated, ubiquitinated by a protein complex formed by
1358 APC, GSK3, Axin and CK1 α and then degraded by the proteasome. Binding of Wnt ligand to
1359 Frizzled receptor and LRP5/6 co-receptor leads to the dissociation of the β -catenin
1360 degradation complex. β -catenin can translocate into the nucleus where it acts as a
1361 transcriptional coactivator for transcription factors of the TCF/LEF family inducing the
1362 expression of specific target genes. In APA as well as in CPA, *CTNNB1* mutations affecting
1363 specific residues of β -catenin lead to constitutive activation of the protein. In APA, mutations
1364 in APC also lead to constitutive β -catenin activation.

1365

1366 **Figure 2. The two current models for APA development. Left panel: Two hit model of**
1367 **APA development.** In ZG cells, activation of specific signaling pathways, such as β -catenin,
1368 lead to abnormal cell proliferation. Abnormal cell proliferation creates a propitious
1369 environment for occurrence of recurrent somatic mutations specifying the pattern of hormonal
1370 secretion. **Right panel: APCC hypothesis.** In ZG cells, occurrence of somatic mutations in a
1371 certain number of APA driver genes, lead to the formation of aldosterone producing cell
1372 clusters (APCC) with autonomous aldosterone production. In a certain number of cases these
1373 structures would evolve towards an aldosterone producing adenoma a possible APCC-to-APA
1374 transitional lesion (pAATL).

1375

1376

Table 1. Clinical and molecular characteristics of patients with APA.

Total n of patients screened*	<i>KCNJ5</i> N (%)	<i>CACNA1D</i> N (%)	<i>ATP1A1</i> N (%)	<i>ATP2B3</i> N (%)	<i>CTNNB1</i> N (%)	Other	Correlations of mutation status	Reference
22	8 (36%)	NA	NA	NA	NA	NA	7/8 patients with <i>KCNJ5</i> mutations were female	(24)
380	129 (34%)	NA	NA	NA	NA	NA	<i>KCNJ5</i> : Higher prevalence in females and younger patients; higher plasma aldosterone at diagnosis; no specific pangenomic transcriptomic profile; no association with pre-operative blood pressure, serum potassium and adenoma size or cure after adrenalectomy Lower relative GIRK4 protein expression in <i>KCNJ5</i> mutated tumors	(145,146)
348	180 (45%)	NA	NA	NA	NA	NA	<i>KCNJ5</i> : Higher prevalence in females, males younger at diagnosis and with larger tumors; no correlation with <i>KCNJ5</i> protein expression	(147)
23	15 (62.5%)	NA	NA	NA	NA	NA	<i>KCNJ5</i> : higher <i>KCNJ5</i> mRNA expression compared to non-mutated tumors	(40)
73	30 (41%)	NA	NA	NA	NA	NA	<i>KCNJ5</i> : larger APA, predominant ZF-like cells, younger patients, higher <i>CYP17A1</i> expression;	(148,149)
91	29 (32%)	NA	NA	NA	NA	NA	<i>KCNJ5</i> : Higher aldosterone levels, lower plasma renin activity, higher ARR higher lateralization index; more frequent contralateral suppression Higher <i>CYP11B2</i> mRNA expression	(48)

308	118 (38.3)	NA	16 (5.2%)	5 (1.6%)	NA	NA	<i>ATP1A1</i> and <i>ATP2B3</i> : more frequent in males, higher preoperative aldosterone concentrations, lower serum potassium concentrations	(27)
152	20 (13.2%)	12 (7.9%)	12 (7.9%)	0/10 exomes	1/10 exomes	NA	<i>ATP1A1</i> and <i>CACNAID</i> : more frequent in older males; smaller APAs with more compact, zona glomerulosa-like cells; <i>KCNJ5</i> : more frequent ZF-like cells, higher <i>CYP11B1</i> mRNA expression: No difference in <i>ATP1A1</i> and <i>CACNAID</i> expression among genotypes	(25)
64	21 (32.8%)	5 (7.8%)	1 (1.6%)	2 (3.1%)	2 (3.1%)	NA	<i>CACNAID</i> : smaller APA, trend towards older age	(26)
59	19 (32%)	NA	5 (8.5%)	3 (5%)	NA	NA	No impact of mutation status on lateralization index and contralateral suppression index	(49)
474	180 (38%)	44 (9.3%)	25 (5.3%)	8 (1.7%)	NA	NA	<i>KCNJ5</i> : Higher prevalence in females and younger patients; higher minimal plasma potassium at diagnosis; <i>CACNAID</i> : smaller adenomas** All mutations: no association with pre-operative blood pressure, serum potassium and adenoma size or cure after adrenalectomy; no correlation with cellular composition nor <i>CYP11B2</i> or <i>CYP11B2</i> expression; no correlation with <i>KCNJ5</i> , <i>CACNAID</i> , and <i>ATP1A1</i> mRNA expression	(30)
112****	44 (39.3%)	NA	7 (6.3%)	1 (0.9%)	NA	NA	<i>ATP1A1</i> , <i>ATP2B3</i> : higher <i>CYP11B2</i> mRNA expression compared to <i>KCNJ5</i> mutated APA	(150)

108	75 (69.4%)	2 (1.9)	3 (2.8)	NA	NA	<i>KCNJ5</i> : younger patients, higher plasma and urine aldosterone levels; significant improvement of left ventricular mass index after surgery; lower post-op SBP and aldosterone levels	
195	48 (24.6%)	NA	NA	NA	NA	<i>Not investigated</i>	(151)
165	90 (54.5%)	5 (3.0%)	10 (6.1%)	5 (3.0%)	NA	<i>KCNJ5</i> : Higher prevalence in females and younger patients; <i>CACNA1D</i> , <i>ATP1A1</i> and <i>ATP2B3</i> : older at diagnosis, more often males with smaller tumors; higher <i>CYP11B2</i> and <i>NPNT</i> mRNA expression compared to APA with <i>KCNJ5</i> mutation; All mutations: No correlation with <i>ATP1A1</i> , <i>ATP2B3</i> or <i>KCNJ5</i> mRNA expression	(50)
69	26 (37.7%)	NA	NA	NA	NA	<i>KCNJ5</i> : Lower relative GIRK4 protein expression in <i>KCNJ5</i> mutated APA; Higher prevalence in females and younger patients; larger tumors and lower plasma potassium	(34)
168	129 (76.8%)	1 (0.6%)	4 (2.4%)	1 (0.6%)	NA	<i>KCNJ5</i> : Higher prevalence in females, larger tumors, higher aldosterone levels and lower minimal serum potassium, higher lateralization index, lower plasma renin activity, higher ARR	(42)
71***	27 (38%)	3 (4.2%)	5 (7%)	1 (1.4%)	NA	<i>KCNJ5</i> : more frequently zona fasciculata-like cells, high <i>CYP11B1</i> protein expression; <i>ATP1A1</i> , <i>ATP2B3</i> and <i>CACNA1D</i> : more frequently ZG-like cells with high <i>CYP11B2</i> protein expression	(152)

90	36 (37.1%)	10 (10.3%)	8 (8.2%)	3 (3.1%)	2 (2.1%)	NA	<i>KCNJ5</i> : Higher prevalence in females, larger tumors, lower pre-contrast Hounsfield units on CT; more frequently ZF-like cells <i>ATP1A1</i> , <i>ATP2B3</i> and <i>CACNAID</i> : more frequent in males, heterogenous cell composition	(28)
148	88 (59.5%)	0	2 (1.4%)	1 (0.7%)	NA	NA	Mutation carriers: younger, higher preoperative aldosterone and ARR, lower serum potassium, higher glomerular filtration rate, lower serum CRP levels, greater chance of recovery from hypertension post-adrenalectomy	(44)
114	86 (75.4%)	1 (0.09%)	0	0	NA	NA	Mutation carriers: younger, lower preoperative serum potassium level, higher LV mass index and significant improvement after surgery; higher mRNA expression of <i>KCNJ5</i> , <i>CYP11B2</i> , and <i>ATP2B3</i> male (but not female) mutation carriers: higher preoperative plasma aldosterone and blood pressure;	(43)
198	92 (46.5%)	3 (1.5%)	6 (3.0%)	3 (1.5%)	10 (5.1%)	NA	<i>CTNNB1</i> : more frequent in females; larger tumors compared to APA without mutation; Higher <i>CYP11B2</i> mRNA expression compared to APA with <i>KCNJ5</i> mutation;	(29)
159	117 (73.6%)	4 (2.5%)	1 (0.6%)	4 (2.5%)	NA	NA	<i>ATPase</i> : tendency to smaller tumors, mainly ZG-like cells <i>CACNAID</i> : tendency to smaller tumors, predominant ZF-like cells <i>KCNJ5</i> : not analyzed in this report	(45)

66	47 (71.2%)	0	0	0	NA	NA	<i>KCNJ5</i> : Higher prevalence in females and younger patients, no association with pre-operative blood pressure, plasma aldosterone, serum potassium, lateralization index, and adenoma size; better cure following adrenalectomy	(46)
219	116 (52.9%)	0	3 (1.4%)	1 (0.5%)	8 (3.7%)		<i>CTNNB1</i> : more frequent in females, older patients, heterogeneous staining of β -catenin and variable expression of gonadal receptors and both <i>CYP11B1</i> and <i>CYP11B2</i>	(99)

*by WES and/or targeted sequencing; **frequency of mutations and associations dependent on center; ***patients included in (30) ;**** included 32 samples from (27). ZF, zona fasciculata; ZG, zona glomerulosa.

Table 2. List of the different mutations identified in APA driver genes.

Gene	Mutations	References first description
<i>KCNJ5</i>	p.Gly151Arg, p.Leu168Arg, p.Thr158Ala	(24)
	p.Gly151Glu	(62)
	p.Ile157del	(153)
	p.Tyr152Cys	(154)
	p.Trp126Arg	(150)
	p.Glu145Gln, p.Arg115Trp, p.Glu246Gly	(34)
	p.Phe154Cys, p.Ile150_Gly151del_InsMet,	(28)
	p.Ser143_ile144del_InsAla	
	p.Ala139_Phe142dup	(155)
<i>ATPIA1</i>	p.Leu104Arg, p.Val332Gly, p.Phe100_Leu104del	(27)
	p.Glu960_Alala963del	(25)
	p.Gly99Arg	(150)
	p.Met102_Leu103del	(42)

	p.Met102_Ile106del, p.leu103_Leu104del, p.Phe959_Glu961del,	(50)
	p.Glu960_Leu694del, p.Phe956_Glu961del	
<i>ATP2B3</i>	p.Leu425_426del, p.Val426_427del	(27)
	p.Val424_Leu425del	(30)
	p.Ala428_Val429del	(156)
	p.Val426_Val429del	(50)
	p.Val422_Val426del_InsSerThrLeu	(42)
	p.Ala428_Leu433del_InsGlyGln	(28)
<i>CACNAID</i>	p.Val259Asp, p.Gly403Argp.Phe747Leu, p.Ile750Met,	(25)
	p.Arg990His	
	p.Gly403Arg, p.Ile750Met, p.Phe767Val, p.Val1373Met	(26)
	p.Ser652Leu, p.Leu655Pro, p.Tyr741Cys, p.Val949Asp,	(30)
	p.Lys981Asnp.Ala998Ile, p.Ala998Valp.Val1151Phe,	
	p.Ile1152Asnp.Val1338Met	
	p.Val401Leu	(50)
	p.Phe747Val	(68)

Table 3. Clinical and genetic characteristics of patients with CPA.

Total n of patients screened*	Clinical phenotype	<i>PRKACA</i> N (phenotype)	<i>GNAS</i> N (phenotype)	<i>CTNNB1</i> N (phenotype)	<i>APC</i> N (phenotype)	Reference
139	59 CS, 40 sCS, 20 APA, 20 NSA	22 (CS)	0 in WES	0 in WES	0 in WES	(75)
63 (55 CPA + 8 ACC)	36 CS, 27 sCS	13 (10 CS, 3 sCS)	3 CS	9 (3 CS, 6 sCS)	0 in WES	(76)
87	87 (CS)	57 (CS)	2 (CS)	1 (CS)	1 (CS)	(77)
64	55 CS, 9 sCS	34 (33 CS, 1 sCS)	11 (10 CS, 1 sCS)	0 in WES	0 in WES	(78)
144	64 CS, 36 sCS, 32 NSA, 4 androgen producing tumors, 8 PBMAH	22 (CS)	ND	ND	ND	(157)
60	36 CS, 22 sCS	12 (11 CS, 1 sCS)	4 (3 CS, 1 sCS [§])	13 (5 CS, 8 sCS [§])	ND	(79)
57	15 CS, 9 sCS, 33 APA	4 CS	5 (2 CS, 1 sCS, 2 APA+sCS)	ND	ND	(81,158)

*by whole exome sequencing and/or targeted sequencing, excluding ACC; CS, overt Cushing syndrome; sCS, subclinical Cushing syndrome; APA, aldosterone producing adenoma; NSA, non-secreting adenoma; ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; [§]including one patient with a double *CTNNB1* + *GNAS* mutation; ND, not determined.

Table 4. Clinical and genetic characteristics of patients with A/CPA

Characteristics	(81)	(85)	(79)	(32)	(69)
Total n of APA patients screened	33	unknown	4	122	1
N of patients with cortisol co-secretion (F:M)	10 (x:x)	3 (3:0)	4	?	1 (0:1)
Clinical phenotype	PA/sCS	PA/sCS	PA/2CS-2sCS	1 case with PA/sCS, 1 with PA only	PA/sCS
<i>KCNJ5</i> mutations	6	2	2	0	1 (somatic)
<i>GNAS</i> mutations	2	Not described	0	Not described	Not described
<i>PRKACA</i> mutations	0*	Not described	0	2	Not described
<i>CTNNB1</i> mutations	Not described	Not described	0	Not described	0
<i>APC</i> mutations	Not described	Not described	Not described	Not described	1 (germline)

*in another paper, the same authors report about the analysis of 33 APA, 11 of them with sCS, with none of them carrying a PRKACA mutation (80). It is unclear, what the overlap is between these patients and those of this reference.




Figure 1




Figure 2